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ABSTRACT 
 
Background:  One in ten people in the U.S. are affected by a substance use disorder 
(SUD), roughly one third of whom are women.  Rates of unintended pregnancy are 
higher in this population than in the general public.  Little is understood about how 
women with SUD use prescription contraception and think about pregnancy. 
Methods:  By analyzing Medicaid claims data and conducting qualitative interviews with 
women with SUD, this doctoral thesis seeks to: 1) compare any use of and consistent, 
continued coverage by prescription contraceptives between women with and without 
SUD; 2) determine the extent to which SUD is associated with pregnancy, abortion, and 
adverse feto-maternal outcomes in women who use prescription contraception; and 3) 
explore facilitators of and barriers to contraceptive utilization by women with SUD, using 
qualitative interviews. 
Results:  Compared to women without SUD, women with SUD are less likely to use any 
prescription contraceptive, particularly long-acting reversible methods.  Among women 
who do use long-acting methods, SUD is associated with less continued, consistent 
coverage by a prescription contraceptive.  Among women who use contraception, SUD is 
also associated with increased odds of abortion.  When interviewed, women with SUD 
report fatalistic attitudes towards pregnancy planning, and have difficulty conceptualizing 
how susceptibility to pregnancy may change over time.  Women with SUD also report 
that pregnancy has substantial impact on their drug treatment prospects. 
Conclusions:  This study is the first to examine contraceptive utilization by women with 
SUD who are enrolled in Medicaid or state-subsidized insurance.  Our study may	help	to	
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inform	clinical	practice	and	policy	development	to	improve	the	reproductive	health	and	wellbeing	of	women	with	SUD. 
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PREFACE 
 
Chapter II of this dissertation is under preparation for publication as: 
 
Griffith, GJ et al.  Prescription Contraceptive Use and Adherence by Women with 
Substance Use Disorders. 
 
Chapter III of this dissertation is under preparation for publication as: 
 
Griffith, GJ et al.  The Association of Substance Use Disorders with Pregnancy, 
Abortion, and Adverse Feto-Maternal Outcomes Among Women on Prescription 
Contraception. 
 
Chapter IV of this dissertation is under preparation for publication as: 
 
Griffith, GJ et al.  Barriers to and Facilitators of Contraceptive Use Among Women 
with Substance Use Disorders. 
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CHAPTER I: 
INTRODUCTION 
 
Over 21.6 million individuals in the United States meet criteria for a substance 
use disorder (SUD), which includes abuse of or dependence on alcohol or other drugs1.  
The majority of individuals with SUD are men2, but the gender gap may be closing in 
younger age groups3. Compared to men, women begin use at an earlier age, progress to 
meet criteria for an SUD more rapidly, and present to treatment with greater medical, 
social, and employment impairment4. 
Pregnancy is a particular concern for young women with SUD due to the 
teratogenic effects of many substances5, as well as the indirect effects on fetal 
development secondary to poor maternal health6.  Moreover, women with SUD are at 
increased risk for unintended pregnancies7, which are independently associated with 
inadequate prenatal care, low birth weight, and prematurity8.  The American College of 
Obstetricians and Gynecologists recommends counseling women with SUD about 
prescription contraception9, but SUD has been associated with lower odds of having, and 
consistently using contraception in selected populations 10,11.  Deepening our 
understanding of contraceptive utilization and decision-making by women with SUD may 
suggest improvements to clinical care and public policy that could reduce rates of 
unintended, complicated pregnancies in this population. 
Pregnancy Intentions 
An unintended pregnancy is one that is unwanted, mistimed, or about which the 
mother is ambivalent12.  In the United States, approximately one in two pregnancies are 
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unintended13.  One of the priorities of Healthy People 2020 is a reduction in the 
unintended pregnancy rate14.  Unintended pregnancies are associated with pregnancy 
complications, including delayed prenatal care initiation15,16, prematurity17,18, poorer 
long-term physical and mental health of the offspring19-21, and poorer maternal-child 
bonding22.  Moreover, unintended pregnancy may negatively impact maternal mental 
health23. 
Rates of unintended pregnancy vary across race, socioeconomic status, and age13.  
Drug use and SUD have been associated with higher rates of unintended pregnancy7.  
One British study found that past-year use of illicit drugs other than marijuana increased 
odds of unintended pregnancy over three-fold24.  As many as 76 – 100% of pregnancies 
among opioid-dependent women are unintended12,25,26.  Approximately equal proportions 
of women with SUD describe their unintended pregnancies as unwanted, mistimed, or 
ambivalent12.  Our understanding of factors influencing how women with SUD think 
about pregnancy is limited. 
Prescription Contraception 
A variety of contraceptive methods are available to women who want to prevent 
pregnancy.  Methods vary in their accessibility, effectiveness, side effect profile, ease of 
use, and ease of discontinuation.  Prescription contraceptive methods are more effective 
at preventing pregnancy than over-the-counter methods, such as condoms27.  Prescription 
contraceptive methods can be divided into irreversible contraception (male and female 
sterilization), long-acting reversible contraception (LARC; copper and hormonal 
intrauterine devices [IUDs], and hormonal implants), and short-acting reversible 
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contraception (SARC; oral contraceptive pills [OCPs], hormonal vaginal rings, and 
hormonal patches, and hormonal depot injections).  Approximately one quarter of U.S. 
women of reproductive age used reversible prescription contraception in 2010, of which 
three-quarters used a short-acting method13.  
Prescription Contraception Initiation and SUD 
Two studies conducted over 20 years ago suggest that SUD is associated with 
lower rates of contraceptive use25,28, but trends in utilization by the general population 
have changed significantly since that time29.  Recent studies have focused on the 
association of SUD with having a prescription contraceptive exclusively in 
adolescents32,33 and veterans with concomitant mental illness11.  No study has examined 
contraceptive use by women with SUD who are enrolled in Medicaid, despite Medicaid’s 
critical role in funding care for SUD34 and for unintended pregnancy35. 
Consistent, Continued Prescription Contraception Coverage and SUD 
Appropriate adherence is critical for the effectiveness of any contraceptive 
method as evidenced by the discrepancy between “perfect-use” failure rates and “typical-
use” failure rates36 (Table 1.1).  Non-adherence can result from inconsistent use (e.g., 
skipping one or more oral contraceptive pills), incorrect use (e.g., not refrigerating a 
hormonal ring), or discontinuation of use.  In the general population, 18 – 27% of women 
use contraception inconsistently or incorrectly, and these women account for 41% of 
unintended pregnancies13.  The amount of effort required of patients for correct, 
consistent contraceptive use varies substantially from method to method.  Because LARC 
methods may only require patient action once every three to ten years for adequate 
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coverage, they have lower typical use failure rates than SARC methods, which require 
daily to monthly patient action27,36. 
Emerging evidence suggests that mental health diagnoses and psychiatric 
wellbeing have a significant impact on the likelihood of consistent use and continuation 
of prescription contraceptives30,31. One recent study of Veterans reported that women 
with comorbid mental illness and SUD had less consistent contraceptive coverage over 
12 months than women without either diagnosis10.  However, though SUD is a risk factor 
for inconsistent use of other medications37-40, no studies to date have isolated the 
association of SUD with consistency of prescription contraceptive use. 
Factors Influencing Initiation, Consistent Use, and Discontinuation of Prescription 
Contraception 
Many factors, both personal and structural, impact when and how women with 
SUD initiate, use, and discontinue prescription contraceptives.  Women with and without 
SUD may face barriers to consistent contraceptive use, including partner non-support of 
contraceptive use, and undesired side effects of the contraceptive25,41. Other barriers are 
unique to or heightened in women with SUD.  Rates of co-occurring mental illnesses, 
which are known to affect how women use contraceptives, are elevated in women with 
SUD.  Many women with SUD also report perceptions of stigma by healthcare 
professionals25,41 that may deter them from seeking a prescription contraceptive, and 
drug-induced memory problems that may affect ability to consistently use medications41.  
Importantly, contraceptive decisions are not exclusively driven by the ease of 
obtaining and using a contraceptive, but also by a woman’s feelings towards pregnancy. 
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Ambivalence or positive feelings about pregnancy strongly influence how adolescents 
use contraception43, but it is unclear how pregnancy intentions drive contraceptive use 
among women with SUD.  The existing literature exploring decision-making around 
contraceptive practices focuses predominately on women with opioid dependence12,25,26, 
but ignores the experiences of women dealing with other SUDs.  A deeper understanding 
of the factors driving how women with SUD use prescription contraception and think 
about pregnancy is important to help clinicians meet the reproductive healthcare needs of 
this population. 
Pregnancy Outcomes to Women with SUD 
Pregnancies among women with SUD, either due to contraceptive non-use, 
inconsistent contraceptive use, or innate contraceptive failure, can have short- and long-
term consequences for both the mother and fetus. The biological effects of specific 
substances overlap, and many women concomitantly abuse multiple substances44.  
Maternal alcohol use is associated with fetal alcohol spectrum disorders (FASDs), which 
present with intellectual impairment, physical defects, growth deficits, central nervous 
system problems, and behavioral disorders45.  FASD complicates 2-5% of births46, and, in 
addition to its serious impact on fetal health, FASD costs the U.S. an estimated $4.0 
billion annually47. 
Illicit substances also have a negative impact on fetal development.  Maternal use 
of opioids, marijuana, or cocaine is associated with growth restriction, low birth weight, 
and poor neonatal outcomes6.  Maternal opioid use is additionally associated with 
chorioamnionitis, intrauterine growth restriction, intrauterine fetal demise, and premature 
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delivery48.  Pregnancies to opioid-dependent mothers can be further complicated by 
neonatal abstinence syndrome (NAS), a form of opioid withdrawal undergone by infants 
at birth49.  NAS-afflicted infants have respiratory, gastrointestinal, and feeding 
difficulties50, frequently resulting in longer hospital stays. The incidence of NAS has 
risen in recent years50, costing the U.S. $720 million annually50.  Cocaine use during 
pregnancy is associated with miscarriage, placental abruption, placenta previa, stillbirth, 
preterm delivery, and intrauterine growth restriction 44,51.  The effects of marijuana and 
amphetamine use during pregnancy are not as well established, but may be associated 
with low birth weight, shortening of gestation, and neonatal withdrawal symptoms6,44.  
Many physicians also discourage breast-feeding by women who use marijuana, though 
transfer via breast milk is minimal52. 
Legal Consequences of Pregnancy in Women with SUD 
Pregnancy may also have unique social and legal consequences for women with 
SUD.  Some states have funded drug treatment programs that are specifically targeted 
towards pregnant women, increasing access to a scarce resource in this vulnerable 
population53.  However, many states have elected to deal with SUD in pregnancy as a 
civil or criminal offense.  For example, substance use during pregnancy was specifically 
criminalized in Tennessee in 2014, and prosecutors in other states have successfully 
argued criminal cases against pregnant women with SUD using other existing laws.  
Furthermore, many states consider substance use during pregnancy an act of child abuse, 
a few states allow involuntary commitment of pregnant women with SUD, and some 
states require healthcare professionals to report substance use during pregnancy53.  
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Massachusetts mandates reporting of substance use during pregnancy, but does not 
consider it a criminal act53.  It has been suggested that laws around mandated reporting, 
prosecution, and involuntary commitment of women with SUD may damage patients’ 
trust in providers, leading to avoidance of prenatal care54. A better understanding of how 
legal sanctions affect pregnant women with SUD and their children is needed to align 
legal and regulatory effort with best practices for maternal and fetal outcomes. 
Specific Aims 
  This dissertation will explore how substance use disorders affect prescription 
contraceptive utilization, and describe the downstream associations with pregnancy and 
birth outcomes.  First, we will analyze any use of and consistent, continued coverage by 
prescription contraception among 47,902 women with and without SUD using 
Massachusetts Medicaid (MassHealth) and state-subsidized insurance claims and 
encounter data from 2010 – 2014.  We then will estimate the extent to which SUD is 
associated with odds of pregnancy, abortion, and adverse feto-maternal outcomes among 
women who used a prescription contraceptive in 2012.  Finally, we will examine how 
women with SUD think about pregnancy and contraceptive use by conducting interviews 
with women from Obstetrics & Gynecology clinics in Worcester, MA.  Interviews will 
discuss factors influencing contraception utilization, including perceptions of pregnancy 
and child-rearing, contraceptive use history, barriers to use, and the influence of 
substance use on contraceptive use.  The specific aims of this dissertation are: 
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Aim 1.  To compare any use of and consistent, continued coverage by reversible 
prescription contraceptives by reproductive-aged women with and without diagnosed 
SUDs who are enrolled in Medicaid or state-subsidized insurance. 
Hypothesis 1a.  Women with diagnosed SUD will be less likely to use prescription 
contraceptives than those without a diagnosis of SUD. 
Hypothesis 1b.  Women with diagnosed SUD who use prescription contraceptives will 
have a lower proportion of days covered by a contraceptive than women without a 
diagnosis of SUD. 
Aim 2.  To estimate the extent to which SUD is associated with odds of pregnancy, 
abortion, and negative feto-maternal outcomes among women enrolled in Medicaid or 
state-subsidized insurance who use prescription contraception. 
Hypothesis 2a. SUD will be associated with increased odds of pregnancy.  The 
association of SUD with increased odds of pregnancy will be stronger for women using 
SARC than for women using LARC. 
Hypothesis 2b.  Among women with a pregnancy, SUD be associated with increased 
odds of abortion and negative feto-maternal outcomes. 
Aim 3.  To explore facilitators of and barriers to initiation and consistent, continued use 
of contraception for women of reproductive age with SUDs, 
 Through these aims, this dissertation will describe and contextualize contraceptive 
practices and pregnancy outcomes by women with SUD.  Findings from this study may 
help inform clinical practice and policy development to improve the reproductive health 
and wellbeing of women with SUD and their children.  
		
Table	1.1.		“Perfect	Use”	and	“Typical	Use”	Failure	Rates	for	Common	Contraceptive	Methods	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Adapted from Trussell, 201136 
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CHAPTER II: 
ANY USE AND CONSISTENT, CONTINUED USE OF PRESCRIPTION 
CONTRACEPTION BY WOMEN WITH SUBSTANCE USE DISORDERS 
 
ABSTRACT 
Background:  Rates of unintended pregnancy are substantially higher among women 
with substance use disorders (SUDs) than the general population.  Emerging evidence 
suggests Veteran and adolescent women with SUD are less likely to have, consistently 
use, and continue use of prescription contraceptives.  Although Medicaid beneficiaries 
have high rates of both SUD and unintended pregnancy, the prescription contraception 
utilization among women enrolled in Medicaid and subsidized insurance is unknown.  
Objective:  To examine to what extent SUD is associated with any use of, selected 
method of, and consistent, continued use of prescription contraceptives among women 
enrolled in Medicaid or subsidized insurance in Massachusetts. 
Study Design:  We conducted a retrospective cohort analysis of Massachusetts Medicaid 
(MassHealth) and Commonwealth Care (a subsidized insurance plan for individuals who 
were not eligible for Medicaid) claims and encounter data between 2010 and 2014 for 
47,902 continuously-enrolled women aged 16-45 years.  SUD was identified by the 
presence at least one International Classification of Disease, Ninth Edition (ICD-9) claim 
for an alcohol or drug use disorder.  We examined the association of SUD with three 
outcomes: 1) any use of a reversible prescription contraceptive during 2012; 2) the 
type(s) of methods used; and, 3) the proportion of days covered by a prescription 
contraceptive in the 365 days following the first prescription contraceptive claim.  We 
also examined whether the association between SUD and consistent, continued 
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contraceptive coverage was different between women using short-acting reversible 
contraception (SARC) and long-acting reversible contraception (LARC). 
Results:  Women with SUD were less likely than women without SUD to use a 
prescription contraceptive at any time during 2012 (19.2% v. 23.9%; adjusted Odds Ratio 
[aOR]: 0.80, p < 0.001).  Among those women who used prescription contraception, 
SUD was associated with decreased LARC use (44.5% v. 42.8%; aOR 0.81, p = 0.003). 
Among women who used LARC, SUD was associated with lower odds of continued, 
consistent contraceptive coverage (aOR: 0.67, p = 0.041).  Odds of consistent, continued 
coverage by SARC methods were not significantly different between women with and 
without SUD. 
Conclusion:  Among women enrolled on Medicaid and subsidized insurance, SUD is 
associated with lower odds of using a prescription contraceptive, and of continued, 
consistent use of LARC methods.  Recommendations encouraging LARC use may not be 
sufficient to reduce rates of unintended pregnancy among women with SUD.  
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INTRODUCTION 
Substance use disorders (SUDs), including abuse of and dependence on alcohol 
and drugs, affect about one in ten people in the United States1.  Roughly one-third of 
people with SUD are women3,55. 
One issue particularly complicated by SUD is pregnancy.  SUD is associated with 
preterm labor, premature rupture of membranes, fetal or maternal death, fetal 
malformation, fetal alcohol spectrum disorder, neonatal abstinence syndrome, intellectual 
disability, and poor growth in utero5,6,9,45,56.  Moreover, unintended pregnancy is more 
common among women with SUD6,12,25,26, which is independently associated with 
inadequate prenatal care, low birth weight, and prematurity8. 
To decrease the incidence of these high-risk pregnancies, the American Congress 
of Obstetricians and Gynecologists recommends prescription contraceptive counseling 
for women with SUD, including discussion of long-acting reversible contraceptive 
(LARC) methods9.  Yet, emerging evidence from Veteran and adolescent populations 
suggests women with SUD are less likely than those without SUD to have, consistently 
use, and continue use of prescription contraceptives10,11.  While Medicaid 
disproportionately funds both SUD care34 and care related to unintended pregnancy35, no 
studies have tracked contraceptive use in an SUD population enrolled in Medicaid or 
subsidized insurance.  This study may help clinicians better understand the contraceptive 
practices of women with SUD, and ultimately improve their ability to meet women’s 
contraceptive needs. 
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One potential tool to reduce disparities in contraceptive utilization by women with 
SUD is the delivery of care through expanded, comprehensive models like the Patient-
Centered Medical Home (PCMH).  The PCMH emphasizes a team-based, patient-centric 
approach to care, utilizing centralized primary care, expanded practice hours, integrated 
care delivery, and enhanced care coordination57.  No studies have yet examined whether 
PCMH enrollment improves contraceptive use in vulnerable populations. 
This analysis of Medicaid and Commonwealth Care (a subsidized insurance plan 
for individuals who are not eligible for Medicaid) claims data was conducted to examine 
associations between diagnosed SUD and use of reversible prescription contraceptives, 
the method(s) selected, and consistent, continued coverage by the selected method.  We 
hypothesize that indicators of reversible prescription contraceptive use and consistent, 
continued coverage will be lower in patients with an SUD diagnosis and that the 
association between SUD and less consistent coverage will be weaker for patients using 
LARC.  We also hypothesize that patients with SUD served by Medical Homes will have 
higher rates of contraceptive use and continued, consistent contraceptive coverage. 
MATERIALS & METHODS 
Data Source 
We conducted a retrospective cohort study of Massachusetts Medicaid 
(MassHealth) and Commonwealth Care claims, using data extracted from the Executive 
Office of Health and Human Services Data Warehouse.  This source contains eligibility 
and demographic information, linked with inpatient and outpatient medical claims and 
managed care encounter data, pharmacy claims, and long-term care claims.  Our study 
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timeframe was from April 1st, 2010 to March 31st, 2014, which included the three years 
during which the Patient-Centered Medical Home Initiative (PCMHI) was conducted, 
plus one year of data prior to its start.  The PCMHI was a demonstration project in 
Massachusetts that provided guidance and, in some cases, financial support to help 
primary care practices transform into Medical Homes. 
Sample 
Our sample included women aged 16-45 years who were continuously enrolled in 
Medicaid or Commonwealth Care, and who demonstrated use of their insurance benefit. 
Commonwealth Care was a program created in 2006 to expand coverage to many low-
income Massachusetts residents who did not previously qualify for Medicaid.  The vast 
majority of Commonwealth Care enrollees became eligible for Medicaid after the 
implementation of the Affordable Care Act.  We defined continuous enrollment as 320 
days or more during 201260, consistent with measures used by the Healthcare 
Effectiveness Data and Information Set (HEDIS), a national quality measurement tool 
developed by the National Committee for Quality Assurance61.  We excluded women 
who had evidence of permanent sterilization, bilateral oophorectomy, or hysterectomy in 
the years 2010 – 2012.  For analysis of consistent, continued contraceptive coverage, to 
ensure full availability of data in the 365 days following the first contraceptive claim of 
2012, we further restricted our sample to women who also had continuous enrollment 
during 2013. 
 
Measures 
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Exposure.  The primary exposure of interest was operationalized as physician-
diagnosed SUD, identified by at least one International Classification of Disease, Ninth 
Edition (ICD-9) claim from 2010 – 2012 in any position for an alcohol use disorder 
(303.x, 305.0x), or drug use disorder (292.x, 304.x, 305.x, excluding tobacco use 
disorders 305.1x).  Women lacking any such ICD-9 claim from 2010 – 2012 were 
classified as not having an SUD.  We conducted sensitivity analyses where we defined 
SUD using only 2012 diagnoses, but did not find any differences in our results. 
Outcomes.  We created a dichotomous indicator of “any use” of prescription 
contraceptives in 2012. We defined “any use” as at least one claim for an office 
procedure indicating contraceptive device placement or prescription fill during 2012; 
women without any claim during 2012 were classified as non-users.  Oral contraceptive 
pills (traditional and extended cycle), transdermal hormonal patches, and vaginal rings 
were identified using National Drug Codes, and depot injections, hormonal implants, and 
IUDs were identified using ICD-9 Procedure and Current Procedural Terminology codes 
indicating placement, removal, or maintenance. 
To examine method selection, women with evidence of prescription contraceptive 
utilization in 2012 were categorized into one of two groups: long-acting reversible 
contraception (LARC) users (IUDs or implants) and short-acting reversible contraception 
(SARC) users (Oral Contraceptive Pills [OCPs], patches, rings, or depot injections). If 
women used both SARC and LARC during 2012, they were categorized as LARC users. 
We chose proportion of days covered (PDC) by a prescription contraceptive as 
our indicator of consistent, continued coverage62.  PDC is an overall indicator of the 
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proportion of time a woman was preventing pregnancy with prescription contraception, 
and captures both how long a prescription contraceptive was continued, as well as the 
consistency of coverage during that time.  PDC does not capture whether a contraceptive 
was used correctly (eg, taken at the same time everyday). 
We created one PDC that included all forms of prescription birth control, such 
that a woman was “covered” if we could identify any method of prescription birth control 
available to her on a given day.  Coverage length was determined by days’ supply for oral 
contraceptive pills, hormonal patches, and vaginal rings.  Coverage periods for depots, 
implants, and IUDs were assumed to be 90 days, three years (1,095 days), and five years 
(1,825 days), respectively, unless a removal code could be identified prior to these times.  
Although copper IUDs last up to 10 years, we were not able to consistently identify IUD 
type, and so we used the more conservative estimate appropriate to the hormonal IUD.  
Because we examined a period shorter than five years, this does not affect our PDC 
estimates.  We identified the first use of a prescription contraceptive during 2012 (the 
“index” claim), and examined coverage by a contraceptive in the 365 days following that 
claim.  When periods of contraceptive coverage overlapped, we excluded one 
overlapping section so as to not double count days covered.  PDC was calculated as the 
proportion of days during which a women was covered by any prescription contraceptive 
in the 365 days following the index claim.  In light of the fact that the minimum PDC for 
adequate contraceptive coverage is unknown, we created three PDC tertiles with equal 
numbers of women in each. 
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Covariates.  Based on Andersen’s Model of Healthcare Utilization, we theorized 
that contraceptive use, method selection, and PDC could be predicted by a combination 
of predisposing factors (age, overall health status, psychiatric comorbidity10,11, coronary 
comorbidity, recent history of pregnancy, recent history of abortion, SUD), enabling 
factors (plan type, disability status, enrollment in the PCMHI), and evaluated need (SUD 
identification by a healthcare provider). Age, plan type, and disability status were 
obtained from the member file.  Race was not included in our models due to high rates 
(34.2%) of missing data.  We hypothesized that expanded access provided by Medical 
Homes might improve contraceptive use in women with SUD, so an indicator was 
included for enrollment in the PCMHI, the Massachusetts demonstration project that 
helped primary care practices become PCMHs.  Overall health status was operationalized 
with the DxCG Score, a classification system developed for the purpose of risk-adjusted 
payments, and used here as a measure of disease burden63.  Psychiatric comorbidity was 
operationalized as presence of ICD-9 codes during 2012 for major depression, bipolar 
disorder, post-traumatic stress disorder, or schizophrenia and other psychoses.  Because 
use of estrogen-containing contraceptives is contraindicated or discouraged in patients 
with excessive coronary risk, we included a variable indicating coronary comorbidity 
(hypertension, venous thromboembolism, coronary artery disease, coronary vascular 
disease, stroke, tobacco use among women age 35 or older).  We hypothesized that 
women in the period soon after a pregnancy or abortion might be additionally motivated 
to contraceptive use, so we included covariates for pregnancy (ICD-9 codes: 632, 634.x, 
650.x – 677.x) during 2011, and abortion (ICD-9 codes: 635.x, 636.x) during 2011.  In 
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recognition of differences in prior authorization procedures for managed care plans that 
could contribute to differences in contraceptive utilization, we included plan type as a 
three-level variable (managed care organization [MCO]; Primary Care Clinician Plan 
[PCC]; and all Commonwealth Care [COM]). 
Analysis 
We conducted univariate tests of normality of continuous variables.  Based on 
non-normal distributions, we categorized age and DxCG score.  Patient demographic and 
comorbidity profiles were described by SUD category.  Differences were tested using 
chi-square tests for categorical variables and student’s t-tests for continuous variables.  
We created separate models to explore our three outcomes:  any prescription 
contraceptive use during 2012 (dichotomous: any use/ no use); type of method used 
(dichotomous: SARC/ LARC); and PDC (ordinal: tertiles).  Any prescription 
contraceptive use and contraceptive method (LARC/SARC) were described with logistic 
models.  Odds of falling into a higher PDC category were described by simple and 
multivariable ordinal logistic models.  Adjusted odds ratios (aOR) for PDC represent 
both the odds of being in the highest PDC tertile versus being in the middle or lowest 
PDC tertiles, and the odds of being in the middle PDC tertile versus being in the lowest 
PDC tertile in women with SUD compared to women without SUD. 
We first created simple regression models with SUD diagnosis as the only 
predictor.  We then created multivariable models using stepwise addition of covariates 
(alpha-to-enter = 0.05; alpha-to-remove = 0.10) 64.  All covariates described above were 
Chapter	II	 	 	
	
19	
tested in each model.  The models described in Tables 2.2 and 2.4 represent parsimonious 
models where all included covariates that met this criterion. 
RESULTS 
Of 67,007 women aged 16-45 years enrolled at any time during 2012, 52,894 
(78.9%) were continuously enrolled.  We excluded 3,330 women (6.3%) with no 
evidence of benefit use during 2012, 1,443 women (2.9%) with a history of permanent 
sterilization, and 219 women (0.5%) with history of a hysterectomy or bilateral 
oophorectomy for a final sample of 47,902 women.  For analysis of PDC, we further 
restricted this sample to 30,353 women continuously enrolled in 2013 (63.4%). 
Demographics 
On average, compared to women without SUD, women with SUD were slightly 
older and were more likely to be white, be enrolled in the PCC plan, be enrolled in a 
PCMHI, qualify for Medicaid through a disability, have had a recent pregnancy, or have 
had a recent abortion.  Compared to women without SUD, those with SUD were in 
poorer health with higher DxCG scores, and were much more likely to be diagnosed with 
a serious mental illness.  Among women with SUDs, the most frequently diagnosed use 
disorders were opioids (58.1%), alcohol (41.6%), cocaine (22.3%), and marijuana 
(21.5%). 
Any Use of a Prescription Contraceptive 
Women with SUD were less likely to use a prescription contraceptive at any time 
during 2012 (19.2% v 23.9%, Odds Ratio [OR]: 0.76, p < 0.001).  This difference 
persisted when adjusting for age, DxCG score, plan type, PCMHI enrollment, 
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gynecological exam, disability status, STI diagnosis, recent history of pregnancy, and 
recent history of abortion (aOR: 0.80, p < 0.001) (Table 2.2). Among women who used 
prescription contraception, odds of LARC use were approximately equal between women 
with and without SUD in unadjusted models (44.5% v. 42.8%; OR: 1.07, p = 0.261).  
However, when adjusting for age, DxCG score, plan, PCMHI enrollment, disability 
status, STI diagnosis, recent history of pregnancy, and recent history of abortion, women 
with SUD had lower odds of using LARC than those without SUD (aOR: 0.81, p = 
0.003) (Table 2.2).  To explore whether increased healthcare access through the PCMHI 
mitigated differences in contraceptive use for women with SUD, an interaction term 
between PCMHI and SUD was tested in each model, but ultimately did not meet criteria 
for inclusion. 
Consistent, Continued Use of Prescription Contraception 
Among the women who used a prescription contraceptive in 2012, we identified 
7,161 women with continuous enrollment in 2012 and 2013.  We excluded 1,809 women 
who used LARC during 2012, but for whom we could not identify the device placement 
date, for a final sample size of 5,352 women. From this sample, three PDC categories 
were created with approximately equal numbers of subjects in each group: lowest PDC 
(PDC ≤ 0.247), intermediate PDC (0.247 < PDC ≤ 0.704), and highest PDC (PDC > 
0.704).  The majority of women on LARC fell into the highest PDC group (78.7%), and 
women on SARC were more commonly in the lowest (41.8%) or intermediate (40.3%) 
PDC groups (Table 2.3). 
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A diagnosis of SUD was associated with lower odds of being in a higher PDC 
tertile in our unadjusted model (OR: 0.82, p = 0.024), but not in our model adjusted for 
DxCG score, plan type, PCMHI enrollment, and STI diagnosis (aOR 0.85, p = 0.083), 
models. In separate models created based on type of contraceptive used, we found that 
the negative association of SUD with PDC tertile was stronger in women using LARC 
(OR: 0.70, 0.079; aOR: 0.67, p = 0.041) than in women using SARC (OR: 0.79, p = 
0.023; aOR: 0.95, p = 0.613) (Table 2.4). Again, to detect any impact of Medical Home 
enrollment on contraceptive use by women with SUD, an interaction term for PCMHI 
and SUD was tested, but not included in the final model. 
 
COMMENT 
Our study, conducted in a large database that demonstrated real-world behavior, 
found that women with SUD had lower odds of using prescription contraception during 
2012 and a lower proportion of days covered over one year for women using LARC 
methods.  SUD was not associated with less consistent, continued contraceptive coverage 
among women using SARC methods.  Our study is the first to isolate the association 
between SUD and consistent, continued contraceptive coverage in any population.  It is 
also the first to study contraceptive use in an SUD population enrolled in Medicaid or 
subsidized insurance, which disproportionately fund both SUD care34 and care related to 
unintended pregnancy35. 
Our findings of an association between SUD and lower rates of contraceptive any 
use and continued, consistent contraceptive coverage are consistent with previous studies 
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of adolescents and Veterans.  One recent study reported that Veteran women with SUD 
had 21 – 27% reduced odds of having any form of prescription contraceptive, compared 
to women without11.  A subsequent paper in the same population reported that women 
with combined mental illness and SUD had fewer months of contraceptive coverage in 
the first year, as well as reduced odds of continuation at 12-months10. In the Veteran 
population described in these studies, however, SUD was not associated with reduced use 
of LARC methods. 
There are several plausible explanations for lower rates of prescription 
contraceptive any use and continued, consistent contraceptive use by women with SUD.  
First, compared to women without SUD, women with SUD may be less sexually active or 
rely more on condoms. However, our finding of elevated STI rates among women with 
SUD suggests that unprotected sexual encounters are at least as prevalent in women with 
SUD as the general population. Existing literature suggests that condom use is less 
prevalent and more inconsistent in substance-using populations65,66.  Literature also 
suggests women with SUD may have higher numbers of sexual partners, and increased 
engagement in commercial sex work67.  However, it should also be noted that STI 
prevalence is only a rough indicator of sexual activity, and differences in the prevalence 
of STIs in the sexual partners of women with SUD may also contribute to the their 
elevated rates of STIs. In either case, our findings highlight the importance of dual use of 
prescription contraception and condoms for adequate protection against unintended 
pregnancy and STIs. 
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Alternatively, the association between SUD and lower contraceptive any use and 
continued, consistent contraceptive coverage could reflect changing pregnancy intentions.  
We found that SUD was associated with lower PDC tertile among women on LARC, but 
not among women using SARC.  Whereas our PDC measure captures both 
discontinuation and inconsistent use of SARC methods, low PDC among LARC users is 
predominately driven by discontinuation. This suggests women with SUD are making an 
active choice to discontinue LARC methods, which could represent a desire to be, or at 
least ambivalence towards becoming, pregnant. Consistent with changing pregnancy 
intentions, qualitative studies have described strong desires for future pregnancy among 
women with SUD using LARC26.  Alternatively, women with SUD may discontinue 
LARC methods due to the end of a relationship, or undesired side effects such as 
menstrual irregularity26. 
Finally, lower contraceptive use and consistent, continued contraceptive coverage 
among women with SUD may result from higher barriers to physician access. All women 
in our study used their healthcare benefit in 2012, but a higher level of involvement with 
the healthcare system may be necessary to initiate or continue prescription contraception.  
For example, a woman could qualify for the study through an emergent ER visit, but lack 
transportation to get to a physician to get a prescription contraceptive.  SUD does appear 
to impact physician access; several small studies have reported that active drug use will 
often be prioritized over healthcare utilization41,68, and others have found that SUD is 
associated with poorer attendance at scheduled physician visits69.  Although one study 
found higher rates of sexual and reproductive health services utilization in women who 
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use substances70, we found decreased rates of gynecological exams in women with SUD, 
which could be indicative of poorer physician access.  
Models integrating sexual and reproductive health with substance use screening 
and treatment could help to alleviate disparities in access, if present71.  However, we did 
not find that one potential such modifier, enrollment in the PCMHI, mitigated the 
association between SUD and contraceptive utilization.  The PCMH is an evolving 
model, and our data cannot identify to what extent women enrolled in the PCMHI 
received expanded services.  Further exploration of expanded care models will be 
necessary to determine their value for increasing contraceptive utilization in marginalized 
populations. 
Limitations 
 Our study has several limitations worth noting.  First, our identification of SUD is 
susceptible to misclassification.  We cannot identify women with SUD who have not 
been diagnosed by providers, and we cannot tell how many of the women we do identify 
are in recovery.  Also, our study necessarily underestimates the number of patients who 
use sterilization or IUDs, as we cannot identify patients for whom procedures were 
conducted prior to 2010. We cannot directly identify patients who are at risk for 
unintended pregnancy, or who solely rely on condoms for pregnancy prevention.  We 
have used STI diagnoses to indirectly adjust for levels of unprotected sexual activity.  
Finally, our data source lacks information on potentially important confounders such as 
income, and has high rates of missing race data. 
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Conclusions 
Despite these limitations, our study presents important findings from a large 
source of reliable data.  Our study adds to the literature by examining contraceptive use in 
a population with low incomes, as indicated by their enrollment in Medicaid or 
subsidized insurance. Ours is also the first to isolate the association of SUD with 
indicators of consistent, continued contraceptive coverage.  Future research that examines 
the association of SUD with discontinuation and inconsistent use as separate outcomes 
may help clinicians better understand factors driving prescription contraceptive use in 
this population. 
		
Table 2.1. Demographic characteristics and comorbidities of reproductive-aged women continuously enrolled in 
Massachusetts Medicaid or Subsidized Insurance in 2012, by Substance Use Disorder (SUD) (N = 47,902)  
 
 
SUD 
N = 6,121 
% 
No SUD 
N = 41,781 
% 
Demographics   
Age (years), mean (SD) ** 30.9 (7.6) 29.9 (8.2) 
     16 – 24 25.5 33.3 
     25 – 34 42.7 36.1 
     35 – 45 31.8 30.6 
Race **   
     Non-Hispanic White 54.9 23.4 
     Non-Hispanic Black 11.9 14.8 
     Hispanic 8.7 16.3 
     Other 1.7 9.6 
     Unknown 22.7 35.9 
   
Health Care Access   
Plan Type **   
     Commonwealth Care (COM) 9.5 20.1 
     Managed Care Organization (MCO) 46.7 48.4 
     Primary Care Clinician (PCC) 43.8 31.5 
Patient-Centered Medical Home (PCMH) Enrollment ** 66.6 59.5 
Disability ** 28.5 9.2 
Gynecological Exam in 2012 ** 16.5 22.1 
   
Medical Conditions   
DXCG Score, mean (SD) ** 2.7 (2.4) 1.0 (1.4) 
     Lowest Quartile 1.9 17.5 
     2nd Quartile 4.4 29.3 
     3rd Q l  27 1 29 3 
         
				
	
		
	
			
	
		
HIV Diagnosis ** 1.7 0.5 
HCV Diagnosis ** 15.4 0.5 
Other Sexually Transmitted Infection (STI) Diagnosis (2012) ** 18.5 16.9 
Recent History of Pregnancy (2011) ** 21.0 18.1 
Recent History of Abortion (2011) ** 3.2 1.9 
   
Serious Mental Illness Diagnosis   
Major Depression ** 27.6 8.0 
Bipolar Disorder ** 25.6 3.1 
Post Traumatic Stress Disorder ** 25.0 4.8 
Schizophrenia & Other Psychoses ** 9.9 1.4 
   
Identified Substance Use Disorders   
Alcohol Use Disorder 41.6 0.0 
Drug Use Disorder   
     Opioids 58.1 0.0 
     Cocaine 22.3 0.0 
     Cannabis 21.5 0.0 
     Other Drug Use Disorder 40.3 0.0 
   
Prescription Contraceptive Use, 2012   
Any Prescription Contraceptive Use, 2012 ** 19.2 23.9 
     Short-Acting Reversible Contraception Use, 2012   
        Oral Contraceptive Pills 6.4 9.5 
        Hormonal Patch or Ring 1.3 1.3 
        Depot Injection 2.5 2.3 
     Long-Acting Reversible Contraception Use, 2012   
        Implant 1.4 1.6 
        IUD 5.9 7.1 
    Multiple Methods 1.7 2.1 
DxCG Score: A summary score developed for the purpose of calculating risk adjusted payments, used here as an indicator of overall disease burden. Higher scores indicate higher disease 
burden.  63 A score of 1.0 indicates average disease burden.  The interquartile range for scores in our sample was 0.233 – 1.702. 
* p < 0.05 by χ2 test 
** P < 0.01 by χ2 test 
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Table 2.2.  Odds of any prescription contraceptive use and long-acting reversible contraceptive use in 2012 among 
women of reproductive age enrolled in Medicaid or state-subsidized insurance (N = 47,902) 
 
 
SUD 
 
 
% 
No SUD 
 
 
% 
Odds Ratio 
 
OR 
(95% CI) 
Adjusted Odds 
Ratio 
aOR 
(95% CI) 
Any Prescription Contraceptive Use, 2012 N = 6,121 N = 41,781   
     No 80.8 76.1 Ref Ref 
     Yes 19.2 23.9 0.76** (0.71-0.81) 
0.80** 
(0.74-0.86) 
Method of Contraceptive Used, 2012 N = 1,175 N = 9,997   
     Short-Acting Reversible Contraceptive 55.5 57.2 Ref Ref 
    Long-Acting Reversible Contraceptive 44.5 42.8 1.07 (0.95-1.21) 
0.81** 
(0.71-0.93) 
Any Prescription Contraceptive Use aOR adjusted for: age, DxCG, plan type, PCMHI enrollment, gynecological exam, disability status, STI diagnosis, recent history of pregnancy, recent 
history of abortion 
Method of Contraceptive Used aOR adjusted for: age, DxCG, plan, PCMHI enrollment, disability status, STI diagnosis, recent history of pregnancy, recent history of abortion 
* p < 0.05 
** P < 0.01 
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Table 2.3.  PDC tertile distribution among women of reproductive age with and without SUD enrolled in Medicaid or 
state-subsidized insurance, by method (N = 5,352)  
 
 Short-Acting Reversible 
Contraception Users 
N = 3,709 
% 
Long-Acting Reversible 
Contraception Users 
N = 1,643 
% 
Lowest Tertile 41.8 10.1 
Middle Tertile 40.3 11.2 
Highest Tertile 17.9 78.7 
 
Lowest Tertile:  PDC ≤ 0.247 
Intermediate Tertile:  PDC > 0.247 & PDC ≤ 0.704 
Highest Tertile:  PDC > 0.704 & PDC ≤ 1 
 
Proportion of Days Covered (PDC): The proportion of days a woman was covered by any reversible prescription contraceptive in the 365 days following the first prescription contraceptive 
use in 2012. 
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Table 2.4.  Association of SUD with higher PDC tertile among women of reproductive age enrolled in Medicaid or 
state-subsidized insurance, by method of prescription contraception used (N = 5,352) 
 
  Stratified Models 
 
Women on Any Reversible 
Contraception in 2012 
 
N =  5,352 
Women on Short-Acting 
Reversible Contraception in 
2012 
N = 3,709 
Women on Long-Acting 
Reversible Contraception in 
2012 
N = 1,643 
 
Odds Ratio 
(OR) 
(95% CI) 
Adjusted Odds Ratio 
(aOR) 
(95%CI) 
OR 
(95% CI) 
aOR 
(95%CI) 
OR 
(95% CI) 
aOR 
(95%CI) 
Higher PDC Tertile 0.82* (0.69 – 0.97) 
0.85 
(0.70 – 1.02) 
0.78* 
(0.64 – 0.96) 
0.95 
(0.76 – 1.17) 
0.70 
(0.49 – 1.00) 
0.67* 
(0.46 – 0.98) 
 
Higher PDC Tertile aOR adjusted for: age, DxCG, plan type, PCMHI enrollment, STI diagnosis 
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Table	2.5	Supplementary	analyses	exploring	the	effect	on	all	models	of	varying	the	window	for	identification	of	
substance	use	disorders	(SUDs)		
 Original Model: 
SUD diagnosis 2010-2012 
 
Model 2: 
SUD diagnosis 2011-2012 
Model 3: 
SUD diagnosis 2012 
 aOR 
(95% CI) 
aOR 
(95% CI) 
aOR 
(95% CI) 
Any Use 0.80** 
(0.74 – 0.86) 
0.76** 
(0.72 – 0.84) 
0.77** 
(0.71 – 0.84) 
LARC Use 0.81** 
(0.71 – 0.93) 
0.78** 
(0.67 – 0.90) 
0.77** 
(0.66 – 0.90) 
Consistent, Continued Use    
     All Contraceptive Users 0.85 
(0.70 – 1.02) 
0.87 
(0.72 – 1.06) 
0.80* 
(0.65 – 0.99) 
     SARC Users Only 0.95 
(0.76 – 1.17) 
0.96 
(0.77 – 1.21) 
0.90 
(0.70 – 1.15) 
     LARC Users Only 0.67* 
(0.46 – 0.98) 
0.73 
(0.49 – 1.09) 
0.64* 
(0.42 – 0.98) 
aOR  Adjusted Odds Ratio 
SARC  Short-Acting Reversible Contraception 
LARC  Long-Acting Reversible Contraception 
 
* p < 0.05 
** P < 0.01 	
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CHAPTER III: 
THE ASSOCIATION OF SUBSTANCE USE DISORDERS WITH PREGNANCY, 
ABORTION, AND ADVERSE FETO-MATERNAL OUTCOMES AMONG 
WOMEN ON PRESCRIPTION CONTRACEPTION 
 
ABSTRACT 
Objectives:  To estimate the association of substance use disorders (SUDs) with odds of 
pregnancy, abortion, and adverse perinatal outcomes among women using reversible 
prescription contraceptives. 
Study Design:  We conducted a retrospective cohort study of women who were enrolled 
in Medicaid or state-subsidized insurance and who used a reversible prescription 
contraceptive during 2012.  Using multivariable logistic regression, we estimated the 
association of SUD with odds of pregnancy, abortion, adverse maternal events, and 
adverse fetal events.  We also explored whether these associations differed between 
women using long-acting reversible contraception (LARC) and women using short-acting 
reversible contraception (SARC). 
Results:  Among 7,062 contraceptive users, we identified 1,833 women with pregnancies 
in 2013 (SUD: 28.9%, non-SUD: 25.6%). SUD was not associated with increased odds of 
pregnancy among women who used SARC (adjusted Odds Ratio [aOR]: 1.20, 95% CI: 
0.97 – 1.47) or among women who used LARC (aOR: 1.00, 95% CI: 0.76 – 1.30).  
Among women who became pregnant, SUD was associated with increased odds of 
abortion (SUD: 19.1%, non-SUD: 11.8%; aOR: 1.58, 95% CI: 1.09 – 2.30). 
Conclusions:  SUD was associated with higher rates of abortion among women who 
used prescription contraception.  A different approach may be required to help women 
with SUD prevent pregnancies when they don’t want to get pregnant. 
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INTRODUCTION 
Approximately one in ten people in the United States suffer from a substance use 
disorder (SUD), which includes abuse and dependence of alcohol and drugs1. Women 
represent roughly one-third of people with SUD3,55.  SUD increases a woman’s risk of 
unintended pregnancy 6,12,25,26, which is associated with inadequate prenatal care, low 
birth weight, and prematurity8.  SUD is also independently associated with many 
maternal complications (preeclampsia, abruptio placentae, placenta previa, preterm labor, 
and death) as well as poor fetal outcomes (fetal malformation, fetal alcohol spectrum 
disorder, neonatal abstinence syndrome, intellectual disability, poor growth, and fetal 
death) 5,6,9,45,51,56. 
Consistent use of effective contraceptive methods reduces rates of unintended 
pregnancy.  However, up to 41% of unintended pregnancies result from inconsistent 
contraceptive use13.  SUDs have been associated with inconsistent use of prescription 
contraception10,11, as well as other medications37,39,40.  Long-acting reversible 
contraceptive (LARC) methods (intrauterine devices [IUDs] and implants) require less 
active participation by users for consistent use.  These methods more effectively prevent 
unwanted pregnancies than short-acting reversible contraception (SARC) methods.  
While we would expect this to be true for women with SUD, no studies have yet 
examined the association of SUD with pregnancy, abortion, and adverse perinatal 
outcomes among women using prescription birth control. 
Among women who do become pregnant, receipt of adequate preconception care 
and early prenatal care are additional important determinants of pregnancy outcomes72,73.  
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The Patient-Centered Medical Home (PCMH) has been suggested as a particularly apt 
vehicle for delivery of preconception and prenatal care74.  The PCMH emphasizes a 
team-based, patient-centric approach to care, utilizing centralized primary care, expanded 
practice hours, integrated behavioral health care delivery, and enhanced care 
coordination57. No studies have yet examined whether pregnancy rates or adverse 
perinatal outcomes are impacted by enrollment in a PCMH. 
We analyzed Medicaid and Commonwealth Care (a state-subsidized insurance 
plan for lower-income individuals who do not qualify for Medicaid) claims data to 
examine the association of diagnosed SUD with odds of pregnancy, abortion, and adverse 
perinatal events in women using prescription contraception.  Because LARC and SARC 
users might have different rates of inconsistent or discontinued contraceptive use, we also 
wanted to examine whether the association of SUD and pregnancy was modified by 
method of contraceptive used.  We hypothesized that SUD would increase the odds of 
pregnancy, abortion, and adverse perinatal outcomes, and that these associations would 
be diminished in women using LARC.  We also hypothesized that enrollment in a 
Medical Home would reduce risk of adverse perinatal outcomes. 
METHODS 
Data Source 
We conducted a retrospective cohort study of Massachusetts Medicaid 
(MassHealth) and Commonwealth Care claims, using data extracted from the Executive 
Office of Health and Human Services Data Warehouse.  This source contains eligibility 
and demographic information, linked with inpatient and outpatient medical claims and 
managed care encounter data, pharmacy claims, and long-term care claims.  We analyzed 
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data from April 1st, 2010 to March 31st, 2014.  This period included the three years of 
implementation of the Patient-Centered Medical Home Initiative (PCMHI), plus one year 
prior to its start.  The PCMHI was a demonstration project in Massachusetts, during 
which primary care practices were provided with guidance and, in some cases, financial 
support, to transform into Medical Homes. 
Sample 
Our sample included women aged 16-45 years who were continuously enrolled 
during both 2012 and 2013 in a Managed Care Organization (MCO) or Primary Care 
Clinician (PCC) plan administered by Massachusetts Medicaid or Commonwealth Care.    
Commonwealth Care, part of Massachusetts Health Reform in 2006, expanded coverage 
to low-income Massachusetts residents who did not previously qualify for Medicaid.  
After implementation of the Affordable Care Act, the vast majority of Commonwealth 
Care enrollees were eligible for Medicaid.  Our enrollment criterion was chosen to be 
consistent with Healthcare Effectiveness Data and Information Set (HEDIS), a national 
quality measurement tool from the National Committee for Quality Assurance61.  To be 
eligible, women had to: 1) have one or more codes indicating the fill of a prescription 
contraceptive, contraceptive injection, or placement of a contraceptive device during 
2012; and 2) demonstrate use of their insurance benefit during 2013. We excluded 
women who had evidence of permanent sterilization, bilateral oophorectomy, or 
hysterectomy in the years 2010 – 2012.  For analysis of abortions and adverse perinatal 
outcomes, we further restricted our analysis to women who became pregnant in 2013. 
Measures 
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Exposure.  The primary exposure of interest was operationalized as physician-
diagnosed SUD, identified by at least one International Classification of Disease, Ninth 
Edition (ICD-9) claim from 2010 – 2013 in any position for an alcohol use disorder 
(303.x, 305.0x), or drug use disorder (292.x, 304.x, 305.x, excluding tobacco use 
disorders 305.1x).  Women lacking any ICD-9 claim for an SUD from 2010 – 2013 were 
classified as not having an SUD.  We conducted sensitivity analyses in which only 
women with a diagnosis of SUD in the last year were identified as having an SUD, but 
did not find any significant differences in our estimates (Table 3.6). 
Outcomes.  Prevalence of pregnancy during 2013 was our primary outcome.  
Pregnancy was identified by the presence of at least one ICD-9 code during 2013 for 
routine prenatal care, routine postpartum care, normal delivery, abortion, miscarriage, or 
perinatal complication.  Women lacking any of these codes were classified as not 
pregnant during 2013. 
Among women who had a pregnancy in 2013, we also explored prevalence of 
abortions, adverse maternal events, and adverse fetal events.  Because the effects of 
specific substances overlap, and many women may concomitantly abuse multiple 
substances44, we elected to create two composite outcomes to track adverse maternal and 
fetal outcomes.  An “adverse maternal event” included placenta previa, maternal 
infection, maternal hemorrhage, preeclampsia, eclampsia, and premature labor.  
Similarly, we explored rates of adverse fetal events, which included fetal death, poor fetal 
growth, neonatal infection, diagnosed fetal alcohol spectrum disorder, neonatal 
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abstinence syndrome, neonatal hemorrhage, digestive problems, and neonatal 
temperature regulation problems. 
Covariates.  Using Andersen’s Model of Healthcare Utilization75, we theorize that 
pregnancy rates will be associated with a combination of predisposing factors (age, 
psychiatric comorbidity10,11, overall health status, sexual activity level, recent pregnancy, 
recent abortion, type of prescription contraceptive used during 2012, SUD), enabling 
factors (plan type, disability status, enrollment in the PCMHI), and perceived need (SUD 
identification by a healthcare provider).  Age, race, enrollment in the PCMHI, and 
disability status were obtained from the member file.  Enrollment in the PCMHI was 
included to evaluate the potential contribution of Medical Home enrollment, through 
improved care access, to improved pregnancy outcomes.  Due to high rates of missing 
data, race was not included in our final models.  We conducted sensitivity analyses with 
different parameterizations of the available race data, but did not find that our results 
differed significantly. 
Psychiatric comorbidity was operationalized as the presence of ICD-9 codes 
during 2013 for major depression, bipolar disorder, post-traumatic stress disorder, or 
schizophrenia and other psychoses.  To capture overall health status, we used the DxCG 
score, a system originally developed for the purpose of risk-adjusted payments63.  
However, we discovered that among women of this age group, DxCG score is largely 
driven by pregnancy, making its inclusion in models as a covariate inappropriate.  In 
recognition of differences in prior authorization procedures for MCO plans that could 
contribute to differences in reproductive healthcare utilization, we included an indicator 
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for 2012 plan type (MCO and PCC). Plan type in 2013 could not be used, as pregnancy is 
a qualifier for particular plan types.  Although we could not directly identify sexual 
activity level from claims data, we identified diagnosed sexually transmitted infections 
(STIs) in 2013 as a proxy for unprotected sexual activity. Type of prescription 
contraceptive used in 2012 was categorized into one of two groups: LARC (IUDs or 
implants) and SARC (oral contraceptive pills, patches, rings, and depot injections).  If 
women used both SARC and LARC during 2012, they were categorized according to the 
last method used in 2012. 
Recent pregnancy and recent abortion were both evaluated as covariates in all 
models. We theorized that recent pregnancy or abortion might influence contraceptive 
consistent, continued use of contraceptives76,77, as well as outcomes for women who did 
become pregnant quickly14,78,79.  Recent abortion was defined as any code for a 
pregnancy termination in 2012.  Any pregnancy that was completed but not terminated in 
2012 (e.g., normal delivery, complicated delivery, or miscarriage) was included as a 
“recent pregnancy.”  We did not include cases of pregnancy without an indication of their 
completion in 2012 to avoid including pregnancies that continued into 2013.  To assess 
for the risk of over-adjustment by including these variables, we also conducted a 
secondary analysis excluding them from our models and found no significant impact on 
the association between SUD and pregnancy or pregnancy outcomes. 
Several maternal comorbidities associated with adverse maternal and fetal 
outcomes (gestational diabetes, pregnancy-induced hypertension, maternal obesity, and 
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plurality of the pregnancy) were also included as covariates in pregnancy outcome 
models, but not in models of pregnancy rates or abortion. 
Analysis 
We categorized age into three groups.  Patient demographic and comorbidity 
profiles were described by SUD category.  Chi-square tests were used to test differences 
in categorical variables, and Student’s t-tests were used to test continuous variables.  
Including all women who used prescription contraception during 2012, we created a 
logistic model to examine odds of pregnancy during 2013.  Among women who became 
pregnant in 2013, we then created three separate logistic models to examine odds of 
abortion, adverse fetal events, and adverse maternal events.  For each of these four 
models, we first created simple logistic models with SUD diagnosis as the only predictor.  
We fit multivariable models using stepwise addition of covariates (alpha-to-enter = 0.05; 
alpha to remove = 0.10) 64.  Indicators for SUD, PCMHI enrollment, and LARC/SARC 
use were all retained in all final parsimonious models, to allow us to comment 
specifically on the associations between these variables and pregnancy outcomes.  We 
theorized that type of contraceptive might modify the association of SUD and pregnancy, 
so we created separate unadjusted and adjusted models for SARC and LARC users.  
RESULTS 
 Of 44,195 women aged 16-45 enrolled at any time during 2013, 33,319 women 
(75.4%) were continuously enrolled during 2012 and 2013. We excluded 1,889 women 
(5.7%) with no evidence of benefit use during 2013, 938 women (3.0%) with a history of 
a permanent sterilization, 139 women (0.4%) with a history of hysterectomy or bilateral 
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oophorectomy, and 316 women (1.0%) with a diagnosis of infertility.  Of the remaining 
30,037 women, we identified 2012 prescription contraceptive use in 7,062 (23.5%). 
Demographics 
 Relative to women without SUD, women with SUD were more likely to be 25-35 
years old, be non-Hispanic white, be enrolled in the PCC plan, and to qualify for 
Medicaid through a disability.  Women with SUD tended to be in poorer health, as 
indicated by higher DxCG scores, and had much higher rates of diagnosed mental illness 
compared to women without SUD.  Rates of infection with hepatitis C virus and sexually 
transmitted infections were also substantially higher in women with SUD.  Women with 
SUD had higher rates of recent pregnancy and of recent abortion.  Diagnosed SUDs 
included opioids (40.7%), alcohol (18.9%), cannabis (12.0%) cocaine (11.3%), and other 
drug use disorder (17.4%). The majority of women, both with and without SUD, used 
only SARC during 2012 (SUD: 57.3%; non-SUD: 57.3%) (Table 3.1). 
Pregnancy 
 Rates of pregnancy were slightly higher in women with SUD than in women 
without SUD (28.9% v. 25.6%; Odds Ratio [OR]: 1.19, 95% Confidence Interval [CI]: 
1.01 – 1.39) (Table 3.3).  However, after adjusting for age, plan type, contraceptive type, 
STI diagnosis, PCMHI enrollment, recent pregnancy, and recent abortion, the confidence 
interval around the estimate of effect included unity (adjusted Odds Ratio [aOR]: 1.12, 
95% CI: 0.95 – 1.31) (Table 3.3).  PCMHI enrollment was associated with slightly 
increased odds of pregnancy (aOR: 1.13, 95%CI: 1.01 – 1.26). When including only 
SARC users, SUD was associated with increased odds of pregnancy (OR: 1.31, 95% CI: 
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1.07 – 1.60), although after adjustment, the confidence intervals included unity (aOR: 
1.20, 95% CI: 0.97 – 1.47).  We found no association between SUD and increased 
pregnancy rates among LARC users (OR: 1.01, 95% CI: 0.78 – 1.32; aOR: 1.00, 95% CI: 
0.76 – 1.30) (Table 3.3). 
Pregnancy Outcomes 
Rates of abortions were higher among women with SUD than women without 
SUD (19.1% v. 11.8%; OR: 1.77, 95% CI: 1.24 – 2.51), and the association of SUD with 
increased odds of abortion persisted after adjustment for age, STI diagnosis, recent 
history of pregnancy, recent history of abortion, and PCMHI enrollment (aOR: 1.58, 95% 
CI: 1.09 – 2.30) (Table 3.4). Rates of adverse fetal events were higher in women with 
SUD compared to those without (17.5% v. 14.5%) (Table 3.2), but confidence intervals 
around our estimate of effect included unity in both unadjusted (OR: 1.25, 95% CI: 0.87 
– 1.79) and adjusted (aOR: 1.33, 95% CI: 0.92 – 1.92) models (Table 3.4).  Our analysis 
did not detect an association between SUD and adverse maternal outcomes (22.0% v 
21.1%; OR: 1.05, 95% CI: 0.76 – 1.45; aOR: 0.91, 95% CI: 0.64 – 1.30) (Table 4).  Type 
of contraceptive did not modify the association between SUD and adverse perinatal 
outcomes (Table 3.4). 
PCMHI enrollment was associated with increased odds of abortion, though the 
confidence interval included unity (aOR: 1.29, 95% CI: 0.94 – 1.76), but was not 
associated with adverse fetal events (aOR: 1.07, 95% CI: 0.81 – 1.41) or adverse 
maternal events (aOR: 1.04, 95% CI: 0.82 – 1.33). 
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DISCUSSION 
 In our analysis of Massachusetts Medicaid and subsidized insurance claims data, 
among women who used any prescription contraceptive in 2012, SUD was not associated 
with increased odds of pregnancy.  Among women who became pregnant, SUD was 
associated with higher odds of abortion.  Our study is the first to examine pregnancy 
outcomes in women with SUD who use prescription contraception. 
 SUDs are associated with inconsistent prescription contraception use10,11, but little 
research has been done looking at how SUD is associated with odds of pregnancy among 
women using contraception.  One study in Vancouver, Canada found a higher-than-
average incidence of pregnancy among injection drug-using women80.  The authors of 
this study attributed the increased incidence to a very low uptake of hormonal 
contraception within the population, but did not look at differences in pregnancy rates 
among women who used prescription contraception. 
 While we found higher rates of pregnancy in contraceptive-using women with 
SUD, we did not find evidence of an association after adjustment for other factors.  This 
suggests that the association we observe between SUD and pregnancy among 
contraceptive-using women may be attributable to other factors associated with SUD, 
rather than SUD itself. 
However, our study shows different estimates of effect for the association of SUD 
with pregnancy among SARC and LARC users. Our finding that SUD is more strongly 
associated with pregnancy among SARC users than LARC users suggests that LARC 
may be superior to SARC in preventing unwanted pregnancies in this population.  
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Barriers to transportation81, housing instability82, drug-induced memory problems 41, or 
the disinhibition associated with SUD4042 may impact the consistent, continued use of 
SARC methods more so than LARC methods.  The increased frequency of physician 
visits required for SARC methods may be more challenging for women with SUD than 
for those without, particularly because women with SUD report perceptions of stigma by 
healthcare professionals25,41.  However, as our study did not randomly assign LARC and 
SARC use to subjects, it is also possible that any differences here may be due to 
differences in the population selecting these methods.  
 We also find higher odds of abortions in women with SUD, regardless of chosen 
contraceptive method.  Consistent with previous literature2412,25,26, this suggests that many 
pregnancies in this population were unintended and ultimately unwanted.  This finding 
emphasizes the importance of providing women with SUD with prescription 
contraceptive methods they are able to easily, consistently use for as long as they desire 
contraception.  We do not find significant associations between SUD and adverse 
perinatal outcomes that have been established in larger studies5,6,9,45,56, possibly because 
our study did not examine infant claims. 
 Although PCMHI enrollment was not associated with adverse perinatal events, 
this finding alone does not preclude the importance of primary care/behavioral care 
integration, preconception care or regular prenatal care as important factors in 
determining pregnancy outcomes.  Our data describes participation in the Massachusetts 
PCMHI, but we cannot evaluate what services are expanded for PCMHI enrollees in our 
sample. 
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Limitations 
 Our study has several limitations.  First, we cannot identify the pregnancy 
intentions of the women in our study.  Secondly, our dataset is limited by the absence of 
information on selected important variables, including income, severity of addiction, 
sexual activity level, and marital status.  We also have high rates of missing race and 
ethnicity data.  Our identification of SUD is also imperfect, and we may incorrectly 
identify women who meet criteria for SUD but who have not yet been identified by a 
provider. 
Conclusions 
Despite these limitations, our study uses a large, reliable data source to ascertain 
information on the pregnancy outcomes of women with SUD.  Our findings add to the 
literature by describing the pregnancy outcomes in women with inconsistent or 
discontinued contraceptive use, rather than outcomes of contraceptive non-users.  The 
association of SUD with higher rates of abortions among women who initiate prescription 
contraception suggests barriers to continued, consistent use of prescription contraceptives 
may be higher for women with SUD than those without.  New approaches to prescription 
contraceptive delivery may help women prevent unwanted pregnancies..
		
Table	3.1.		Demographic	characteristics	and	comorbidities	of	contraceptive-using	women	of	reproductive	age	
continuously	enrolled	on	Massachusetts	Medicaid	or	state-subsidized	insurance	in	2012	and	2013,	by	
Substance	Use	Disorder	(SUD)	(N	=	7,062)		
 
 SUD 
N = 850 
mean (SD) or % 
No SUD 
N = 6,212 
mean (SD) or % 
Demographics   
Age (years), mean (SD)** 27.2 (6.2) 27.3 (7.0) 
     16 – 24 41.2 43.1 
     25 – 34 46.8 40.6 
     35 – 45 12.0 16.3 
Race/ethnicity**   
     Non-Hispanic White 51.4 26.1 
     Non-Hispanic Black 15.3 15.2 
     Hispanic 8.4 16.0 
     Other 2.0 7.1 
     Unknown 22.9 35.7 
   
Health Care Access   
Plan Type**   
     Commonwealth Care (COM) 15.1 19.7 
     Managed Care Organization (MCO) 64.2 63.1 
     Primary Care Clinician (PCC) 20.7 17.2 
Patient-Centered Medical Home Initiative (PCMHI) 
Enrollment 
62.6 60.7 
Disability** 19.5 6.9 
   
Medical Conditions   
DXCG Score, mean (SD) ** 2.3 (2.1) 1.0 (1.3) 
     Lowest Quartile 4.5 19.6 
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     2nd Quartile 10.0 29.2 
     3rd Quartile 30.2 28.4 
     Highest Quartile 55.3 22.8 
Obesity 13.1 14.4 
Hepatitis C Virus (HCV)** 8.9 0.4 
Sexually Transmitted Infection (STI) Diagnosis* 21.8 18.8 
Recent History of Pregnancy (2012)* 24.5 20.7 
Recent History of Preterm Delivery (2012) 1.9 1.3 
Recent History of Abortion (2012)** 12.0 5.9 
   
Serious Mental Illness (SMI) Diagnosis   
Major Depression** 23.9 7.8 
Bipolar Disorder** 20.3 2.9 
Post Traumatic Stress Disorder** 19.1 4.5 
Schizophrenia & Other Psychoses** 6.8 1.1 
   
Prescription Contraceptive Use, 2012   
     Short-Acting Reversible Contraception (SARC) use only 57.3 57.3 
     Long-Acting Reversible Contraception (LARC) use only 36.9 37.3 
     SARC and LARC use 5.8 5.4 
DxCG Score: A summary score developed for the purpose of calculating risk adjusted payments, used here as an indicator of overall disease burden. Higher scores indicate higher disease 
burden. 63 A score of 1.0 indicates average disease burden.  The interquartile range for scores in our sample was 0.255 – 1.688. 
 
* p < 0.05 by χ2 test 
** P < 0.01 by χ2 test 
 
§ p < 0.01 by Student’s t-test 
§§ p < 0.001 by Student’s t-test 
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Table 3.2.  Pregnancy, and adverse perinatal outcomes in 2013 to previous prescription contraceptive users enrolled in 
Medicaid or state-subsidized insurance, by Substance Use Disorder (SUD) Status (N = 7,062) 
 
 SUD 
% 
No SUD 
% 
 N = 850 N = 6,212 
Any Pregnancy, 2013* 28.9 25.6 
   
 N = 246 N = 1,587 
Abortion** 19.1 11.8 
Adverse Fetal Outcomes 17.5 14.5 
     Preterm Birth (PTB) and Small for Gestational Age (SFGA) 5.7 3.3 
     Fetal Distress (Respiratory Distress, Infection, Hemorrhage, 
Digestive, Temperature Regulation, FASD, NAS) 
4.9 4.0 
     Fetal Loss (Stillbirth, Fetal Demise, Spontaneous Abortion) 8.9 8.4 
Adverse Maternal Outcomes 22.0 21.1 
     Preterm Labor 6.9 6.4 
     Infection** 4.9 2.4 
     Placenta Previa and Hemorrhage 15.5 14.9 
* p < 0.05 by χ2 test 
** P < 0.01 by χ2 test 
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Table 3.3.  Influence of Substance Use Disorder on Odds of Pregnancy During 2013, Overall and Stratified by Type of 
Last Contraceptive Used in 2012, for Women Enrolled in Massachusetts Medicaid (N = 7,062) 
 
  Stratified Models 
 
Women on Any Reversible 
Contraception in 2012 
 
N =  7,062 
Women on Short-Acting 
Reversible Contraception 
in 2012 
N = 4,259 
Women on Long-Acting 
Reversible Contraception 
in 2012 
N = 2,803 
 
Odds Ratio 
(OR) 
(95% CI) 
Adjusted Odds 
Ratio (aOR) 
(95%CI) 
OR 
(95% CI) 
aOR 
(95%CI) 
OR 
(95% CI) 
aOR 
(95%CI) 
Any Pregnancy, 2013 1.19* (1.01 – 1.39) 
1.12 
(0.95 – 1.32) 
1.31** 
(1.07 – 1.60) 
1.20 
(0.97 – 1.47) 
1.01 
(0.78 – 1.32) 
1.00 
(0.76 – 1.30) 
Adjusted model covariates   age, plan type, contraceptive type, STI diagnosis, PCMHI enrollment, recent pregnancy, and recent abortion 
* p < 0.05 
** P < 0.01 
 
 
 
  
  
			
	
				
		
		
Table 3.4.  Influence of Substance Use Disorder (SUD) on odds of abortion and adverse perinatal outcomes, overall and 
stratified by type of last contraceptive used in 2012, for women enrolled in Massachusetts Medicaid who were pregnant 
in 2013 (N = 1,833) 
 
 
Women on Any Reversible 
Contraceptive who Became Pregnant 
N =  1,833 
Women on Short-Acting 
Reversible Contraception 
(SARC) 
N = 1,126 
Women on Long-Acting 
Reversible Contraception 
(LARC) 
N = 707 
 
Odds Ratio 
(OR) 
(95% CI) 
Adjusted Odds 
Ratio (aOR) 
(95%CI) 
OR 
 
(95% CI) 
aOR 
 
(95%CI) 
OR 
 
(95% CI) 
aOR 
 
(95%CI) 
Abortion 1.77** (1.24 – 2.51) 
1.58* 
(1.09 – 2.30) 
1.76** 
(1.15 – 2.70) 
1.56 
(1.00– 2.46) 
1.72 
(0.92 – 3.23) 
1.60 
(0.82 – 3.15) 
Adverse Fetal 
Event 
1.25 
(0.87 – 1.79) 
1.33 
(0.92 – 1.92) 
1.31 
(0.86 – 2.00) 
1.34 
(0.87 – 2.07) 
1.07 
(0.54 – 2.10) 
1.40 
(0.67 – 2.91) 
Adverse Maternal 
Event 
1.05 
(0.76 – 1.45) 
0.91 
(0.64 – 1.30) 
1.03 
(0.69 – 1.55) 
0.90 
(0.58 – 1.39) 
1.08 
(0.63 – 1.87) 
0.86 
(0.47 – 1.60) 
Abortion Model Covariates   age, STI diagnosis, recent abortion, recent pregnancy, PCMHI enrollment 
Adverse Fetal Event Covariates   age, plan type, disability status, pregnancy-induced hypertension, gestational diabetes, multiple pregnancy, PCMHI enrollment 
Adverse Maternal Event Covariates  age, plan type, PTSD, recent pregnancy, recent abortion, pregnancy-induced hypertension, gestational diabetes, multiple pregnancy, PCMHI enrollment 
* p < 0.05 
** P < 0.01 
  
				
		
			
	
		
Table 3.5.  Categorization of Reversible Contraceptive Methods as Short-Acting Reversible Contraception (SARC) or 
Long-Acting Reversible Contraception (LARC) 
 
 
Contraceptive Category Contraceptives Included Claims Identification 
Short-Acting Reversible Contraception (SARC) 
Oral Contraceptive Pills ICD-9, NDC, HCPCS 
codes 
Hormonal Patch NDC, HCPCS codes 
Vaginal Ring NDC, HCPCS codes 
Depot Injection NDC, HCPCS codes 
Long-Acting Reversible Contraception (LARC) 
Hormonal Implant ICD-9, CPT, HCPCS codes 
Copper IUD ICD-9, CPT, HCPCS codes 
Hormonal IUD ICD-9, CPT, HCPCS codes 
NDC   National Drug Codes 
HCPCS  Healthcare Common Procedure Coding System 
ICD-9  International Classification of Disease, Ninth Edition 
CPT  Common Procedural Terminology 
  
				
		
			
	
		
Table 3.6 Supplementary analyses exploring the effect on all models of varying the window for identification of 
substance use disorders (SUDs) 	
 Original Model: 
SUD diagnosis 2010-2013 
 
Model 2: 
SUD diagnosis 2011-2013 
Model 3: 
SUD diagnosis 2012-2013 
Model 4: 
SUD diagnosis 2013 
 aOR 
(95% CI) 
aOR 
(95% CI) 
aOR 
(95% CI) 
aOR 
(95% CI) 
Pregnancy 
All Users 1.10 
(0.94 - 1.30) 
1.07 
(0.91 - 1.27) 
1.03 
(0.87 - 1.24) 
0.94 
(0.82 - 1.23) 
SARC Users 1.18 
(0.96 – 1.46) 
1.15 
(0.93 - 1.42) 
1.19 
(0.95 - 1.48) 
1.08 
(0.84 - 1.39) 
LARC Users 0.98 
(0.75 – 1.28) 
0.96 
(0.73 - 1.27) 
0.82 
(0.61 - 1.11) 
0.72 
(0.51 - 1.03) 
Abortion 
All Users 1.58* 
(1.09 - 2.30) 
1.55* 
(1.05 - 2.29) 
1.50 
(0.99 - 2.28) 
1.73* 
(1.09 - 2.73) 
SARC Users 1.56 
(0.99 - 2.45) 
1.42 
(0.89 - 2.29) 
1.52 
(0.94 - 2.48) 
2.22** 
(1.32 - 3.72) 
LARC Users 1.60 
(0.82 - 3.15) 
1.84 
(0.93 - 3.66) 
1.36 
(0.61 - 3.03) 
0.65 
(0.21 - 2.01) 
Adverse Fetal Events 
All Users 1.33 
(0.92 - 1.93) 
1.39 
(0.95 - 2.03) 
1.35 
(0.90 - 2.02) 
1.37 
(0.86 - 2.18) 
SARC Users 1.34 
(0.87 - 2.07) 
1.33 
(0.85 - 2.08) 
1.20 
(0.75 - 1.92) 
1.13 
(0.66 - 1.96) 
LARC Users 1.40 
(0.67 - 2.91) 
1.72 
(0.82 - 3.60) 
2.06 
(0.93 - 4.55) 
2.69* 
(1.09 - 6.64) 
Adverse Maternal Events 
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All Users 0.91 
(0.64 - 1.30) 
0.89 
(0.62 - 1.29) 
0.87 
(0.59 - 1.29)  
1.08 
(0.70 - 1.66) 
SARC Users 0.91 
(0.59 - 1.41) 
0.94 
(0.60 - 1.48) 
0.88 
(0.55 - 1.42) 
1.09 
(0.65 - 1.83) 
LARC Users 0.87 
(0.47 - 1.61) 
0.76 
(0.39 - 1.48) 
0.83 
(0.40 - 1.69) 
1.06 
(0.47 - 2.38) 
aOR  Adjusted Odds Ratio 
SARC  Short-Acting Reversible Contraception 
LARC  Long-Acting Reversible Contraception 
 
* p < 0.05 
** P < 0.01 
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CHAPTER IV: 
BARRIERS TO AND FACILITATORS OF CONTRACEPTIVE USE AMONG 
WOMEN WITH SUBSTANCE USE DISORDERS 
 
ABSTRACT 
Purpose:  Women with substance use disorders (SUDs) are at particularly high risk for 
unintended pregnancy. SUD may be associated with lower any use and consistent, 
continued use to prescription contraception, but little is understood about how women in 
this population think about pregnancy and make contraceptive decisions. 
Methods:  We conducted in-person, individual interviews with pregnant or recently 
pregnant women with SUD from two obstetrics & gynecology clinics in Worcester, MA.  
Verbatim transcripts were analyzed using the constant comparative method. 
Results:  Five themes emerged that described the way in which women with SUD 
approach contraception and pregnancy planning.  1) Unintended pregnancies were 
viewed positively by many women.  2) Women frequently relied on an external locus of 
control, such as fate or God, to manage their fertility.  3) Active drug use decreased 
women’s ability to access contraception.  4) Women did not always account for past 
experiences or possibility of future changes when making contraceptive decisions.  5) 
Pregnancy sometimes facilitated access to particular SUD treatment services, but women 
may also avoid treatment for fear of social or legal consequences. 
Conclusions:  For some women with SUD, positive feelings about pregnancy may 
influence contraceptive decision-making.  Pregnancy may be a motivator for sobriety, but 
reducing barriers to treatment entry will be important for improved care in this 
population.  
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INTRODUCTION 
About half of pregnancies in the United States are unintended83, and 40% of these 
pregnancies are terminated83.  Unintended pregnancies are associated with delayed 
prenatal care initiation15,84, premature delivery17,18, poorer long-term physical and mental 
health of the offspring19-21, poorer maternal mental health23, and impaired maternal-child 
bonding22. 
Disparities in rates of unintended pregnancy exist across race, age, and 
socioeconomic status83.  Women with substance use disorders (SUDs) are one group at 
particularly high risk for unintended pregnancy, with rates as high as 76 – 100%12,24-26.  
Pregnancies in women with SUD are complicated by increased risk of preterm labor, 
poor in-utero growth, fetal malformation, fetal alcohol spectrum disorder, neonatal 
abstinence syndrome, and fetal and maternal death5,6,9,45,56. 
Emerging evidence suggests women with SUD are less likely to have and 
consistently use prescription contraception10,11, but little is understood about the factors 
influencing contraceptive decision-making by women with SUD.  One study described 
reasons for use and discontinuation of particular contraceptive methods in this 
population, but did not discuss broader concepts such as pregnancy intention26. 
 We examine data from in-depth, semi-structured individual interviews with 
pregnant and recently pregnant women with SUD to describe the factors influencing their 
contraceptive utilization and pregnancy intentions.  Understanding how women with 
SUD think about pregnancy and contraception may help to inform clinical practice and 
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policy development to improve delivery of reproductive health services to this group of 
women. 
METHODS 
Study Sample 
We used purposive sampling to recruit participants from two general obstetrical 
and gynecological (OB/Gyn) clinics and one specialized clinic for pregnant women with 
opioid dependence in Worcester, MA.  Potential subjects were referred to study staff by 
their treating OB/Gyn physician, resident physician, nurse practitioner, or social worker. 
Eligible participants were 18-45 years old, heterosexually active within the past six 
months, identified as having an SUD by the referring provider, English-speaking, and 
cognitively intact.  Providers were asked to refer women who abused or were dependent 
on alcohol or any illicit or prescription drug.  Women with active SUD, as well as those 
with a history of SUD, were included.  Currently institutionalized or incarcerated women 
were excluded.  We aimed to recruit 15-20 women in the study, the point at which we 
hypothesized we would hit thematic saturation.  The University of Massachusetts 
Medical School Institutional Review Board approved this study, and verbal consent was 
obtained from all subjects at the time of enrollment. 
Development of Interview Guide 
Initial development of the semi-structured interview guide was informed by 
Gelberg’s Behavioral Model for Vulnerable Populations, an expansion of Andersen’s 
Model of Healthcare Utilization (Figure 4.1) 85.  The initial guide was reviewed by 
treating OB/Gyn physicians and SUD treatment providers for clarity and content.  During 
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data collection, members of the study team iteratively reviewed collected responses to 
evaluate whether questions in the interview guide were clearly communicating intended 
meaning.  No changes were made to the study guide in this process.  Interview guide 
topics included perceptions of pregnancy and child-rearing, history of prescription 
contraceptive use, barriers to any use and consistent, continued use to contraceptives, and 
the influences of substances on contraceptive use (Table 4.1).  
Semi-Structured Interviews 
In-person, semi-structured individual interviews were conducted at the time of 
enrollment, or were scheduled at the subject’s convenience.  Interviews lasted 30-45 
minutes, were conducted in a private space by a single member of the study team, and 
were audio recorded with the subject’s permission.  Subjects were given a $40 gift card 
for their participation.  The interviewer and primary investigator discussed weekly 
whether interviews were continuing to generate new or different information, or whether 
concept saturation had been reached.  These two study members agreed concept 
saturation had been reached after 15 interviews, and after conferring with the rest of the 
study investigators, recruitment was closed. 
Analysis 
All interviews were transcribed verbatim by a member of the study team.  Each 
transcript was reviewed for accuracy of the transcription.  The first three transcripts were 
independently coded by two members of the study team, who then met to resolve 
discrepancies and create an initial codebook.  The initial coding structure was developed 
using the framework of Gelberg’s Model as well as concepts emerging from the data.  
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The remaining twelve interviews were then coded by a single member of the study team 
using the constant comparative method86.  Coding was reviewed weekly with a second 
study team member.  New codes and alterations to codes were discussed between the two 
members of the analysis team, and any changes to the codebook were applied to all 
transcripts.  All investigators reviewed and agreed upon interpretation of thematic 
summaries and final analysis.  
RESULTS 
Between November 2015 and January 2016, we conducted 15 interviews with 
women with SUD who received care at one of the study locations.  Thirteen women 
(87%) were pregnant at the time of the interview; the remaining two women had 
delivered within the last year.  The median age was 25 years, and participants ranged 
from 22 – 32 years.  Seven women (47%) had completed high school, and only one 
woman had graduated from college.  Ten women (67%) reported cohabitating with a 
stable partner; eleven (73%) reported sexual activity in the last month.  Most women 
were multiparous, and nine women (60%) had a history of miscarriage.  A history of 
polysubstance use was present in all but one woman.  Four women (27%) reported using 
methadone or buprenorphine for management of an opioid use disorder (Table 4.2). 
We identified five themes that impacted the way in which women used 
contraception and/or planned their pregnancies.  First, women in our sample generally 
viewed current pregnancy favorably, and almost never described their pregnancy as 
unwanted.  Second, many participants had specific ideas of how to time pregnancy in 
their lives, but were also comfortable relinquishing fertility control to external forces.  
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Third, even though women in our sample had no problems getting contraception when 
sober, active drug use decreased their access.  Fourth, contraceptive decision-making was 
grounded in women’s current situation, and did not always account for past experiences 
or possible future changes in risk.  Fifth, women perceived pregnancy as a facilitator of 
access to substance use treatment, but it could also present barriers to SUD treatment.  
We describe each theme in more depth below. 
Continued unintended pregnancies were not identified as unwanted 
Many women in our sample identified their current pregnancies as unintended, 
but not as unwanted. Many women reported feeling thrilled when they found out they 
were unexpectedly pregnant.  One woman described her reaction to finding out about her 
unintended pregnancy: “And then [the technician] put the noise on [the ultrasound], and 
there was the heartbeat. And I’m screaming and crying outta joy …  I was very excited to 
see and hear that” (S1).  Even in situations that were less than ideal, women were still 
enthusiastic about unintended pregnancies.  One woman, who became pregnant in a 
period when she and her partner were using heavily, explained even though “timing 
could’ve been better,” they “were definitely excited” (S6).  
 Though pregnancy was exciting for most women, it could also come with 
negative consequences, leading to conflicted feelings.  One woman whose partner did not 
want more children explained, “when I found out I was pregnant, I was excited, but 
scared at the same time to tell him” (S1).  For another woman, unintended pregnancy was 
accompanied by worries about losing custody: “my first pregnancy… [I] was very [um] 
excited about… and like this time around, I’ve had just a lot of stress… thinking about 
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[um] just the worst happening, cause I don’t have custody of my [other] son” (S8).  
Several women in the study had undergone or considered and rejected abortions for 
unintended pregnancies in the past. 
Women wanted to control the timing of their pregnancy, but also accepted an 
external locus of control 
Many women in our sample wanted to control the timing of their pregnancy to 
meet their concept of what a “family” should resemble, or to fit with certain life goals.  
Many women wanted to time their pregnancies to facilitate the development of sibling 
bonds: “I’m a product of five [siblings] and we’re close together… and we grew up as 
such a tight knit clan… so that to me was really important” (S12).  Another woman 
explained she didn’t want to have kids “back to back , ‘cause then there’s no nurture 
time” (S1). 
Women in our sample wanted to have a steady relationship, adequate income, and 
stable housing before getting pregnant.  One postpartum woman who was about to start a 
long-acting contraceptive explained, 
I would like the option [to get pregnant] to be there in a year – say 
in a year we buy this big beautiful house, and you know, things are 
going so well, and the wedding has happened… I don’t want the 
door to be closed for three years (S7). 
 
Like this participant, many women were eager to avoid contraceptive methods that they 
perceived would not be flexible when they wanted to become pregnant: 
Well, once you have the shot… that’s that for X amount of time… 
it’s just so final, it’s like they’re deciding for you how long you 
need to … wait before you think about having another child (S14). 
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 However, despite having ideas about ideal pregnancy timing, women in our 
sample did not always actively try to prevent pregnancy.  As one woman who became 
pregnant while not using contraception explained, 
I wasn’t pregnancy planning, but I wasn’t not pregnancy planning, 
if that makes sense. Like, I wasn’t trying to get pregnant, but I 
wasn’t avoiding it either (S13). 
 
Instead, many women accepted an external locus of control87, such as fate or God, over 
their fertility. One postpartum woman who was very eager to avoid pregnancy until her 
husband returned from active military service still felt, “if [she] was to get pregnant … 
well, that’s the way God wanted it to be” (S15).  For some women, this may have been 
the result of perceived inability to control their fertility or other aspects of their lives; as 
one women explained, “it’s like nothing pretty much goes as planned, I’ve seen” (S1).   
Women had few structural barriers to prescription contraception, except when 
actively using 
When sober, most women in our sample did not report structural barriers to 
accessing prescription contraception.  Women reported that they were able to see a 
physician for contraception when they needed to.  One woman explained that she’d 
“always had a doctor,” and even when they were unavailable, she felt she could get 
contraception at Planned Parenthood (S6).  However, as one woman described, physician 
visits could be onerous, and would sometimes influence choice of method: 
I didn’t like [the shot] because I had to go to the doctor’s and get 
it done so [if I] like was doing something, then I had to take time 
out of my life to go to the hospital and then go see my doctor (S5). 
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Two women in the sample reported that transportation problems could impair physician 
or pharmacy access.  Because one woman “never had reliable transportation,” she 
“couldn’t make it to … doctors to talk to them to get the prescription” (S12). 
Cost of prescription contraceptives was generally considered manageable by the 
women in our study.  Insurance coverage was common, and women were confident their 
prescription contraceptives would be covered: 
I actually got billed for this IUD for $6,800, and I’m don’t even 
care about. I’m not worried about it, cause I’m sure my insurance 
… will eventually cover it (S15). 
 
However, one woman who had considered using condoms for birth control in the past 
noted she felt she would have to “cut down on sex” to afford them (S8). 
Although this group of women reported few access issues while sober, active drug 
use could decrease physician contact and subsequently, access to contraception.  One 
woman said: 
Well, [uh] like I said, [um] when you’re using drugs… not going to 
the doctor is a big thing. Nobody really goes to see the doctor 
when they’re, you know, on a drug run (S2). 
 
Another woman missed several appointments to have a Mirena placed because, as she 
explained, “keeping appointments is super, super hard” when using drugs (S4).  
Decreased physician contact seemed to stem primarily from decreased motivation for 
contraceptive use and health promotion more generally.  One woman said that during 
periods of use, her “life wasn’t about not having a child, or taking care of [her] body” 
(S7).   
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In choosing contraception, women had difficulty incorporating past experience and 
planning for future changes 
When evaluating their perceived need for contraception, the women in our study 
focused predominately on their present circumstances.  Many women would stop using 
contraception when they ended a committed relationship, and not account for the 
possibility of a new relationship or casual partners.  As one woman, who was not in a 
committed relationship at the time of her delivery, explained, “I never think to get [the 
IUD after delivery] … because that’s not my plan…  If I was gonna be actively having 
sex with somebody, then I could see, you know, I need it” (S5).  Subsequently, women 
needed immediate coverage when they were sexually active again: “I need something 
that’s gonna work like today.  I need something that’s not gonna take a month to kick in” 
(S15).  One woman, who had become pregnant after starting a new relationship without 
contraception, said she “just never think[s pregnancy is] gonna happen so fast” (S3). 
Conversely, women sometimes had difficulty applying past experiences with 
pregnancy and contraception to current decision-making.  Many women in our sample 
had experienced contraceptive failures with particular methods in the past.  For some, 
these failures would inform their current method selection; one woman reported that she 
now avoided the vaginal ring, because she had previously become pregnant while using it 
(S5).  However, another woman adamantly continued her oral contraceptive pill use 
despite multiple unintended pregnancies, saying it “doesn’t 100% work, but for the most 
part, [it] was working” (S14). 
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Pregnancy increased the desire for sobriety and impacted perceived access to 
treatment 
For many women who were actively using when they became pregnant, 
pregnancy became an impetus to sobriety and other life improvement: “we were losing 
everything… and then we found out I was pregnant and it was just like a total … turn 
around” (S6).  When describing her extra motivation to get clean, one pregnant woman 
explained she could “hide [substance use] from her kids, but [she] can’t hide it from this 
one” (S12). 
Many women felt their access to SUD treatment was limited, but some felt 
pregnancy could improve their access.  One woman, who had been trying unsuccessfully 
to get into a residential program for a year and a half, explained “it’s very difficulty 
getting sober nowadays… they don’t have the right resources” (S3).  Pregnancy, 
however, might push women up the priority list for treatment, increasing women’s ability 
to access the specific services they wanted, and even potentially helping them regain 
custody of other children:   
I think in the back of my mind, I wanted to [get pregnant] because 
… my boyfriend and I wanted to get into this one specific 
program… that you can go together… if you’re pregnant, you can 
get in without [a referral from the Department of Children and 
Families (DCF)], so that was always kinda in the back of my head. 
So it wasn’t like I was trying to get pregnant on purpose… but I 
felt like I wanted to be a mother and I felt like there was no other 
way that I was gonna get my son back (S8). 
 
 However, some women saw negative consequences to treatment during 
pregnancy.  Several women expressed concern over how use of medication-assisted 
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therapy (methadone and buprenorphine) for the treatment of an opioid use disorder might 
affect their fetus: 
I have the Subutex [buprenorphine], but really that’s my biggest 
fear and I kind of feel sad – I might cry – but I kind of feel sad 
cause I feel like I’m already bringing my poor baby into this world 
with – it’s like a shitty situation for a baby (S13). 
 
For other women, fear of involvement with DCF deterred treatment-seeking during 
pregnancy.  One woman who had lost her children after entering a residential treatment 
facility described treatment programs as “the fastest way to lose your children” (S14).  
Another woman said she would have abstained from medication-assisted therapy if she 
knew the extent to which DCF would be involved:  
I had assumed if you’re taking illicit street drugs, [DCF would] 
get involved, [um] but I had no idea if you were on maintenance … 
that they could come in and do what they do.  I think that if I had 
known [um] about DCF, though, it definitely would have been very 
different. I would’ve said [um] I’ll get off [buprenorphine] and 
then [um] once I give birth, I’ll get back on (S8). 
 
DISCUSSION 
Our study of pregnant and postpartum women with SUD gives important insight 
into pregnancy planning and contraceptive use in this population.  Many women in our 
study had positive or neutral feelings towards pregnancy, and allowed external forces 
partial control over their fertility.  For women who wanted to prevent pregnancy, active 
drug use could make getting prescription contraception more difficult.  Contraceptive 
choices were often made with little thought towards the future or consideration of past 
experiences.  Women who became pregnant might see changes in the availability of SUD 
treatment. 
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The women in our sample were generally positive or neutral about their 
pregnancies, identifying many as unplanned or poorly timed, but not unwanted.  This 
may partly be related to women’s reliance on external forces to control their fertility.  
Increasingly, researchers are recognizing that the dichotomous label “unintended” or 
“intended” may be inadequate to describe many pregnancies88.  Several studies have 
established an association between substance use and higher rates of unintended 
pregnancy7,12,24, but few identify whether these pregnancies were mistimed, unwanted, or 
ambivalent.  As our sample was made up of women who elected to continue their current 
pregnancies, our study was not designed to comment on women with SUD who had 
unwanted pregnancies.  Rather, our study provides some insight into a group of women 
who have received less attention: those who continued their pregnancies. 
When sober, women in our study generally reported ease in accessing and using 
contraception, and were not limited by cost, physician access, or contraceptive 
availability.  However, active drug use often resulted in decreased physician contact, and 
subsequently, missed opportunities for contraceptive uptake. Other studies have also 
demonstrated heightened structural barriers to contraceptive utilization with active drug 
use25,89.  The relatively strong access to contraception for women in our sample while 
sober may reflect high rates of insurance coverage in Massachusetts, expansions in 
contraceptive coverage implemented through the Affordable Care Act90, or our sampling 
strategy selecting for women who were established in the healthcare system.  
Nonetheless, our findings suggest that laws and policies requiring a physician visit for 
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initiation or continuation of prescription contraception may represent a burden for women 
with active SUD.  
Women’s difficulty incorporating past experience and planning for future changes 
could be explained by a tendency toward present time orientation. Individuals with a 
stronger present time perspective base decisions on concrete, immediate factors and place 
significantly less emphasis on events that occurred in the past or that might occur in the 
future91.  Some studies suggest present time orientation is stronger among individuals 
with SUD92,93.    
Importantly, many women in our study describe how pregnancy impacted SUD.  
We found that pregnancy may represent a window of increased motivation for sobriety in 
the same way it has been shown to motivate other lifestyle changes94.  However, 
perceived social and legal consequences may represent a barrier to SUD treatment and 
prenatal care95.  While some states fund SUD treatment programs specifically targeted 
toward pregnant women, others criminalize substance use during pregnancy53.  To reduce 
barriers to care entry, the American Congress of Obstetricians and Gynecologists had 
called for the retraction of punitive legislation against pregnant women with SUD96. 
Limitations 
Our study was not designed to represent women with SUD who are not already 
established in the healthcare system, or those who elect to terminate their pregnancies.  
Our study is also susceptible to the risk of recall and social desirability biases, 
particularly with regards to reported pregnancy intentions, substance use, and sobriety 
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intentions.  Finally, we were not able to pilot our semi-structured interview questions 
prior to our study. 
Implications for Future Research and Clinical Practice 
This study’s finding that pregnancy intentions are fluid in women with SUD may 
help inform contraceptive counseling for these women.  Our findings also stress that 
barriers to initiating and continuing prescription contraceptives should be made as low as 
possible to enable full-spectrum contraceptive access for women with SUD, 
We also find that unmet need for SUD treatment may increase during pregnancy.  
Our study supports the importance of SUD treatment services targeted to the needs of 
pregnant women, and emphasizes the importance of delicate management of pregnancy 
in the context of SUD.  Our study also suggests that, despite some expanded treatment 
availability for pregnant women with SUD, fear of losing custody of children to a child 
protection agency due to perceived neglect or abuse may actually deter treatment-
seeking.  Reducing legal and social consequences of treatment-seeking during pregnancy 
may help improve care for women with SUD and their children. 
 
	 	 	
	
Table 4.1.  Semi-structured Interview Guide 
 
 
Grand Tour Questions 
How they decide to use birth control or not 
How they decide what method to use or not 
 
Pregnancy Perceptions 
Their plans for children 
What it did mean or would mean for them to become pregnant 
Their perceived pregnancy risks 
Discussions with doctors about their pregnancy planning 
 
Contraceptive Use 
What kinds of advice they have received about birth control 
Who has given them birth control advice 
Qualities that make a birth control method useful or less useful 
Reasons they stopped using birth control in the past 
Methods they have avoided using, and why 
Any times they had difficulty getting birth control when they wanted 
Any times they had difficulty using birth control in the way it was supposed to be used 
Any ways in which alcohol or drug use affected their sexual activity 
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Table 4.2.  Demographic Characteristics of Participating Women 
 
Characteristic No. (%) 
Age, years, median (range) 25 (22 – 32) 
Highest level of education  
    Some High School 3 (20) 
    High School Diploma 7 (47) 
    Some College 4 (27) 
    College Graduate 1 (7) 
Relationship Status  
    Cohabitating Relationship 10 (67) 
    Non-Cohabitating Relationship 2 (13) 
    On-Off Relationship 0 (0) 
    Not Currently in Relationship 3 (20) 
Sexually Active in Last Month 11 (74) 
Parity, median (range) 3 (1 – 14) 
History of Miscarriage 9 (60) 
History of Abortion 3 (20) 
Currently Pregnant 13 (87) 
Substances Used in Last 12 Months  
    Alcohol 6 (40) 
    Prescription Drug 10 (67) 
    Street Drug 14 (93) 
Currently on Opioid Agonist Treatment 4 (27) 
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Figure 4.1.  Application of the Behavioral Model for Vulnerable Populations to Contraceptive Use in Women with SUD 
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CHAPTER V: 
DISCUSSION AND CONCLUSIONS 
 
This dissertation estimates and contextualizes the association of SUD with any 
use and consistent, continued use of prescription contraceptives, pregnancy, abortion, and 
adverse feto-maternal outcomes.  Unintended pregnancies, already common in the 
general population13, are even more prevalent among women with SUD7.  Pregnant 
women with SUD and their fetuses face higher risks for many complications, making it 
particularly important to prevent unwanted pregnancies in this population, and to quickly 
identify unplanned but wanted pregnancies for appropriate management. Evidence 
suggests SUD is associated with lower rates of having and consistently using 
contraception among Veteran women10,11. 
This doctoral thesis: 1) compares any use and consistent, continued use of 
prescription contraception between women with and without SUD; 2) determines the 
extent to which SUD is associated with pregnancy, abortion, and adverse feto-maternal 
outcomes in women who use contraception; and 3) explores facilitators of and barriers to 
contraceptive utilization by women with SUD, using qualitative interviews.  We found an 
association of SUD with lower odds of contraceptive use in a civilian sample enrolled in 
Medicaid or state-subsidized insurance.  Among this population, SUD was also 
associated with lower rates of consistent, continued use of Long Acting Reversible 
Contraceptive (LARC) methods.  Among women who got pregnant while using 
contraception, abortion rates were higher for those with SUD than for those without.  
Importantly, in speaking to women with SUD, we found that “unintended” pregnancies 
were not always “unwanted” pregnancies, and that many women were primarily focused 
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on the present when thinking about pregnancy.  Some women reported that pregnancy 
increased their desire for and access to substance use treatment, but fear of involvement 
by child protective services prevented some women from seeking treatment. 
Differences in Contraceptive Use for Women with SUD 
 The analysis of Medicaid and Commonwealth Care claims data conducted in Aim 
1 demonstrated that women with SUD were less likely to use any form of prescription 
contraception.  As discovered in our qualitative interviews, this could partly result from 
increased structural barriers to care during active use, such as limited access to physicians 
or the pharmacy. However, women also reported that the decision not to use prescription 
contraception was sometimes driven by a perceived low immediate risk of pregnancy, 
often in the context of a dissolved relationship.  It is important to note that a different 
sampling strategy to identify women not already established in care might find additional 
structural barriers to contraceptive use, such as prohibitive cost, for women with SUD. 
 If women with SUD did use a prescription contraceptive, they were less likely to 
use LARC methods, compared to their counterparts without SUD.  Though most 
interviewed women expressed interest in simplified contraceptive regimens like those of 
LARC, many were hesitant to use LARC methods.  Several women expressed concern 
about the “flexibility” of long-acting methods; women wanted to be able to get pregnant 
quickly when they were ready, and worried that LARC methods could not be stopped as 
easily as SARC methods.  Again, given our selected sample, we cannot exclude the 
possibility that some women with SUD may face heightened structural barriers to LARC 
placement.  In particular, LARC method uptake may be inhibited for some women with 
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SUD due to substantial upfront out-of-pocket expense97, or by clinic policies requiring 
multiple physician visits or sexual abstinence for method placement98.  In our qualitative 
study, women did express that onerous care processes could affect their selection of 
contraceptive method. 
 Aim 1 analysis also demonstrated that SUD was associated with less consistent, 
continued use of LARC, but not SARC.  This finding was surprising in light of data 
suggesting that women with SUD may have more difficulty adhering to intensive 
regimens, such as those required for SARC use40.  When evaluating this apparent 
contradiction, one must first consider the measure we chose to examine consistent, 
continued contraceptive use.  Our PDC measure examined the proportion of time a 
woman was in possession of her medication, but it may not be a perfect representation of 
her actual contraceptive use.  PDC is a more accurate measure of actual use for LARC 
methods than it is for most forms of SARC, which rely on a patient taking the 
medication.  It may be that the relationship of SUD with actual contraceptive use, rather 
than observed use, varies more predictably across SARC and LARC users.  Future 
studies using different measures of coverage by LARC and SARC might explain this 
apparent discrepancy. 
Our qualitative findings from Aim 3 suggest two additional possible explanations 
for discontinuation of LARC methods.  First, women may discontinue contraception 
because they are interested in becoming pregnant.  Alternatively, women may 
discontinue LARC methods during periods when they feel they are less susceptible to a 
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pregnancy, such as after the end of a relationship, not accounting for the possibility of 
casual partners or a new relationship.  
Pregnancy Rates and Adverse Feto-Maternal Outcomes Associated with SUD 
 In our Aim 2 analysis, we found that SUD was not associated with increased odds 
of pregnancy.  Interestingly, though we were unable to demonstrate statistical 
significance, our findings suggested that SUD may be associated with increased odds of 
pregnancy in SARC users more than in LARC users. This finding would be expected 
based on previous literature demonstrating less consistent use of prescription 
contraception in women with SUD10, but is surprising in light of our Aim 1 findings that 
SUD was associated with inconsistent and discontinued use only among LARC users.  
This is another finding that may be the result of imperfect measures, as observed 
contraceptive use is a weaker representation of actual use for SARC methods than for 
LARC methods, and inconsistent use or discontinuation may be higher among SARC 
users than we observe. 
 Alternatively, this discrepancy might be explained by differences in patterns of 
contraceptive use between SARC and LARC users.  If LARC users discontinue use only 
when they are at lower risk for pregnancy, such as after the end of a committed 
relationship, it might partially explain how SUD could negatively impact our PDC 
measure among LARC users without impacting pregnancy rates.  In our interviews, 
women with SUD commonly reported stopping contraceptive use because they ended a 
committed relationship.  Conversely, low PDC values for SARC users might represent 
inconsistent use during times of regular sexual activity, which would result in a higher 
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effect on pregnancy rates.  Our overall PDC measure, which captured both inconsistency 
and discontinuation in one measure, was not sensitive to these differences.  Future work 
examining types of non-adherence in this population could give further insight into 
barriers to contraceptive use. 
 Among women who became pregnant, SUD was associated with elevated odds of 
abortions.  This finding gives important context to the insights on pregnancy intentions 
gleaned from our interviews.   While we emphasize in our Aim 3 analysis that many 
unintended pregnancies in women with SUD are wanted, our findings in Aim 2 stress that 
SUD is also associated with an increased risk of unwanted pregnancy.  Our interviews 
were not designed to comment on the portion of unintended pregnancies to women with 
SUD that are unwanted, though others studies have found that about a third are unwanted, 
a third mistimed, and a third ambivalent12.  Future research will be necessary to explore 
barriers to contraceptive use and adherence among women with unwanted pregnancies. 
 We did not find statistically significant associations between SUD and adverse 
fetal or adverse maternal outcomes.  These associations have been widely demonstrated 
in previous literature.  Our analysis, which only used maternal claims data, was not 
optimally designed to detect this association. 
Insights into Contraceptive Decision-Making by Women with SUD 
 Pregnancy intentions have substantial influence over contraceptive use, but are 
essentially unmeasurable in claims data.  Women in our sample often left pregnancy 
planning to fate, but when they did describe specific plans, these plans changed as their 
circumstances evolved.  However, women often based contraceptive decision-making on 
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their current situation only, which sometimes left them scrambling for effective 
contraception or vulnerable to unintended pregnancy when circumstances changed.  One 
possible solution to overcome this barrier in women with SUD would be to meet 
contraceptive needs in real time through a major shift in the provision of contraception.  
Though our sample did not identify many structural barriers to obtaining contraception, a 
few did describe their need for immediate contraceptive coverage in cases of 
unanticipated, casual partners or when their relationship status changed.  Policies 
requiring one or more physician visits for contraceptive access may result in significant 
delays, particularly for women without established primary care physicians.  Over-the-
counter contraceptives99, online and app-based contraceptive prescribing100, and mail-
order contraceptives101 may each hold promise for improving real-time access to 
contraceptive care for women with SUD.  Emergency contraception may be another 
method equipped to provide real-time access to women with SUD, though our interviews 
did not explicitly explore emergency contraceptive use.  Future studies will need to 
evaluate the acceptability and the impact of such programs, especially on marginalized 
populations. 
 The subsequent effects of pregnancy on other aspects of women’s lives cannot be 
ignored.  Many women described pregnancy as a motivator for sobriety, though sobriety 
was not always maintained after the pregnancy.   This suggests, similar to studies of other 
health behaviors, that pregnancy might be a window for behavior change and health 
improvement.  It is important to remember there may be pent-up demand for 
comprehensive care for women with SUD, who in our study reported decreased physician 
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contact during periods of active drug use.  Pregnancy may represent an opportunity to 
address some of these back-logged health concerns, including SUD treatment.  
 However, pregnancy may also increase barriers to medical and substance use 
treatment for women with SUD.  In particular, several women feared that seeking 
substance use treatment could result in involvement of child protective services and 
subsequent loss of custody. The possible harm created by policies around mandated 
reporting and criminal or civil liability of pregnant women with SUD has been debated 
for several decades.  Existing literature suggests that mandated reporting policies damage 
the patient-doctor relationship54,102, and may result in decreased prenatal care103, 
potentially leading to adverse feto-maternal outcomes.  The American Congress of 
Obstetricians and Gynecologists has gone as far as to recommend that physicians work 
with lawmakers to retract punitive legislation against pregnant women with SUD96.  
Although Massachusetts does not officially consider SUD in pregnancy a criminal act or 
an act of child abuse53, our study demonstrated that mandated reporting and the resulting 
consequences may negatively impact women with SUD. 
Limitations 
 Both of the data sources used in this dissertation only identify women who have 
some exposure to the healthcare system.  This limits our study’s generalization to the 
many women with SUD who have limited contact with the healthcare system. However, 
compared to women with SUD who have no healthcare interface, women in our study 
may represent a group that may be more easily reached by possible interventions. 
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 Our claims data is also limited by several poor quality or absent measures.  We 
have high rates of missing race data.   We are only able to capture a rough proxy for 
sexual activity.  We are also missing information in these analyses on condom use, 
marital status, and pregnancy intentions.  Finally, our measure for identification of SUD 
may miss women who meet criteria for SUD, but who have not yet been identified by the 
medical profession.  We have attempted to partially address some of these topics in our 
qualitative analysis. 
Future Research 
 Future research will be necessary both to hone our understanding of the 
population we study in this sample, and to expand our knowledge of women with SUD 
who are not currently engaged in the healthcare system.  In future studies, sources with 
more sensitive measures of consistent, continued contraceptive use will be needed to 
establish the mechanism of SUD’s association with adherence and pregnancy outcomes. 
These studies will ideally measure closer estimates of actual adherence, such as self-
reported adherence, and will examine discontinuation and short gaps of coverage as 
separate outcomes.  Additionally, careful evaluation in larger samples of women with 
SUD of the impact of laws on mandated reporting of child abuse or neglect will be 
necessary to establish whether such policies do more harm than good. 
Conclusions 
 Compared to women without SUD, those with SUD have lower rates of 
prescription contraception any use and continued, consistent use.  Women with SUD also 
had a heightened incidence of pregnancy, though this finding did not appear to be 
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exclusively due to SUD.  Among contraceptive users who become pregnant, SUD is 
associated with higher rates of abortion.  Women in this group frequently identify an 
external locus of control when pregnancy planning, and struggle to incorporate past 
experience or anticipated future changes into current contraceptive choices.   Pregnancy 
may increase access to substance use treatment programs, but fears of child protective 
service involvement may pose a barrier to pregnant women seeking treatment. 
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